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  I 
Summary 
 
Acute lung injury (ALI) is a life threatening heterogeneous lung disease caused by a variety 
of intra- and extra-pulmonary inflammatory insults, including ventilator-induced lung injury, 
sepsis and gastric aspiration. So far no curative therapy is available for patients suffering 
from ALI and its more severe form acute respiratory distress syndrome (ARDS), which have 
a mortality of approximately 40%. Animal models are indispensable to elucidate the 
pathomechanisms of ALI and to develop successful therapeutic strategies. Although mice 
are the most frequently used species in laboratory practice, their small size poses a 
challenge regarding the measurement of respiratory and cardiovascular parameters. As a 
result, mouse models giving comprehensive information on the mechanisms of ALI under 
consideration of the physiological consequences are largely lacking. The present thesis 
aimed to examine the pathomechanisms of ALI in different injury models under consideration 
of clinically relevant physiological parameters. 
 
Therefore, a mouse intensive care unit (ICU) was developed that facilitates non-injurious 
mechanical ventilation under permanent physiological monitoring resulting in stable 
pulmonary and cardiovascular functions. For this purpose the role of recruitment manoeuvres 
(RM) at low and moderately high levels of tidal volume (VT) (8 versus 16 mL/kg) and positive 
end-expiratory pressure (PEEP) (2 versus 6 cmH2O) was examined. The current study 
demonstrated that protective non-injurious ventilation of mice requires the application of 
recurrent short RM to avoid atelectasis and further confirmed a protective effect of low VT 
and an increased PEEP level. Stable cardiovascular functions were achieved by intra-arterial 
volume substitution, regulation of body temperature and adequate anaesthesia. This setup 
provided all necessary parameters to determine experimental ALI, including oxygenation, 
pulmonary inflammation, oedema formation and histopathology, and is therefore useful for 
studies on ALI. 
 
A further objective was to examine the effect of a lethal systemic dose tumour necrosis factor 
(TNF) on the lungs of wild-type and acid sphingomyelinase-deficient (ASM-/-) mice. The pro-
inflammatory cytokine TNF and the ceramide-generating enzyme ASM both play an 
important role in the pathogenesis sepsis, which is the main cause for extra-pulmonary ALI. 
The mouse ICU with its life supporting features facilitated to conduct this study. Despite of 
the supportive strategies, TNF caused septic shock, which was lethal in a significant number 
of wt mice. Of note, ASM-/- mice were protected from the cardiovascular depression and 
mortality, validating a pivotal role of ASM in sepsis. Somewhat surprisingly, TNF-induced 
sepsis did not cause lung injury. 
Summary 
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Finally, a model was required that causes a reproducible lung injury and allows the 
investigation of the effectiveness of therapeutic drugs in ALI, in particular the usefulness of 
steroids, which is currently under debate. For this purpose the model of acid-induced lung 
injury was chosen, because it resembles important clinical features of intra-pulmonary ALI. 
Instillation of acid with pH 1.5 caused inflammation and profound structural changes in the 
lung, leading to a loss of lung functions and severe hypoxemia. Treatment with the 
glucocorticoid dexamethasone proved to be anti-inflammatory, but did not prevent 
physiological dysfunction. In contrast, acid with pH 1.8 induced moderate lung injury with 
mild hypoxemia and predominantly inflammatory processes that were susceptible to 
dexamethasone. For the first time it was shown in an animal model of intra-pulmonary lung 
injury that steroid treatment significantly improved not only neutrophil recruitment and 
oedema formation, but also lung functions and oxygenation. A further therapeutic approach 
with the anti-inflammatory drug quinine failed to improve lung injury.  
 
In conclusion, the mouse ICU established here allows non-injurious ventilation under 
monitoring of clinically relevant parameters, provides life supporting measures, as shown in 
the TNF model, and is useful to conduct injury models. A final cluster analysis revealed three 
patterns of ALI: a ‘classical’ inflammation-dependent pathway and two injury mechanisms 
that are not related to inflammation, namely low-volume injury and chemical damage. These 
results suggest that the clinical effectiveness of anti-inflammatory drugs, such as steroids, 
may depend on the aetiology of ALI.  
   
  III  
Zusammenfassung 
 
Akutes Lungenversagen (Acute Lung Injury/ALI) ist eine heterogene Lungenerkrankung, die 
durch eine Vielzahl von intra- und extra-pulmonalen Stimuli ausgelöst werden kann. Dazu 
gehören unter anderem der beatmungsinduzierte Lungenschaden, Sepsis und die Aspiration 
des Mageninhaltes. Bislang gibt es keine kurative Therapie für ALI und seine schwerere 
Form Acute Respiratory Distress Syndrome (ARDS). Die Mortalität der Patienten mit 
ALI/ARDS liegt deshalb bei ca. 40%. Tiermodelle sind unentbehrlich, um die 
Pathomechanismen zu erforschen, die zu ALI führen, und um wirksame Therapien zu 
entwickeln. Mäuse sind die am häufigsten eingesetzte Spezies in experimentellen 
Tiermodellen. Die Messung von respiratorischen und kardiovaskulären Parametern stellt 
jedoch bedingt durch ihre kleine Größe eine Herausforderung dar. Bisher gibt es kaum 
Mausmodelle für ALI, die einen umfassenden Einblick in die Mechanismen der Entstehung 
des Lungenschadens bieten und gleichzeitig die physiologischen Konsequenzen beleuchten. 
In der aktuellen Studie sollten die Pathomechanismen von ALI in verschiedenen 
Schadensmodellen unter Einbeziehung physiologischer Parameter untersucht werden. 
 
Das erste Ziel dieser Studie bestand darin, eine Maus-Intensivstation zu etablieren, die es 
ermöglicht, Mäuse unter permanenter Überwachung respiratorischer und kardiovaskulärer 
Parameter zu beatmen. Es sollten Bedingungen definiert werden, unter denen diese 
Parameter über mehrere Stunden konstant bleiben. Von besonderem Interesse war dabei 
die Auswirkung von Rekrutierungsmanövern (RM) bei niedrigem und moderat erhöhtem 
Tidalvolumen (VT) (8 versus 16 mL/kg) sowie verschiedenen positiv endexpiratorischen 
Drücken (PEEP) (2 versus 6 cmH2O). Die aktuelle Studie zeigt, dass eine protektive 
Beatmung von Mäusen die Applikation von regelmäßigen RM zur Vermeidung von 
Atelektasen erfordert. Des Weiteren sind ein niedriges VT und moderater PEEP nötig, um die 
Lunge nicht durch die Beatmung zu schädigen. Stabile Kreislaufbedingungen wurden durch 
intra-arterielle Volumengabe, Regulation der Körpertemperatur und eine angemessene 
Anästhesie erreicht. Das hier etablierte Beatmungsmodell liefert alle Parameter die nötig 
sind, um experimentelles ALI zu diagnostizieren, einschließlich von Oxygenierung, 
pulmonaler Entzündung, Ödembildung und Histopathologie, und bietet dadurch eine 
optimale Grundlage für Schadensmodelle. 
 
Ein weiteres Ziel war es, erstmalig den Effekt einer letalen systemisch applizierten Dosis 
„tumour necrosis factor” (TNF) auf die Lunge zu untersuchen. Es wurden Wildtyp und Saure 
Sphingomyelinase-defiziente (ASM-/-) Mäuse in diese Studie eingeschlossen. Das pro-
inflammatorische Zytokin TNF und das Ceramid-generierende Enzym ASM spielen beide 
eine wichtige Rolle in der Pathogenese der Sepsis, welche die Hauptursache für extra-
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pulmonales ALI ist. Die Maus-Intensivstation erwies sich als sehr geeignet, diese 
Untersuchung durchzuführen. Trotz der lebenserhaltenden Maßnahmen war die TNF-
induzierte Sepsis in einer signifikanten Anzahl von Wildtyp Mäusen letal. Interessanterweise 
waren die ASM-/- Mäuse vor kardiovaskulärer Dekompensation und Mortalität geschützt, 
wodurch gezeigt werden konnte, dass die ASM beim letalen Verlauf der Sepsis eine 
entscheidende Rolle spielt. Überraschenderweise wurde jedoch durch die TNF-induzierte 
Sepsis kein Lungenschaden verursacht. 
 
Abschließend wurde ein intra-pulmonales Schadensmodell benötigt, in dem ein 
reproduzierbarer Lungenschaden die Grundlage für die Erforschung therapeutisch wirksamer 
Medikamenten liefern sollte. Im Vordergrund stand dabei die Untersuchung der Wirksamkeit 
von Steroiden bei ALI, die bislang kontrovers diskutiert wird. Zu diesem Zweck wurde das 
Modell des Säure-induzierten Lungenschadens gewählt, da es wichtige klinische Merkmale 
von ALI widerspiegelt. Die Instillation von Säure mit pH 1.5 verursachte sowohl Entzündung 
als auch strukturelle Veränderungen in der Lunge, begleitet von einer Beeinträchtigung der 
Lungenmechanik und schwerer Hypoxämie. Eine Behandlung mit dem Glucocorticoid 
Dexamethason wirkte anti-entzündlich, verhinderte aber nicht die physologische Dysfunktion. 
Im Gegensatz dazu induzierte die Instillation von Säure mit pH 1.8 einen moderaten 
Lungenschaden, der vornehmlich durch inflammatorische Vorgänge und moderate 
Hypoxämie charakterisiert war und durch Dexamethason vollständig verhindert werden 
konnte. Im Rahmen des hier etablierten Tiermodelles wurde zum ersten Mal die Wirksamkeit 
von Steroiden bei intra-pulmonalem ALI nicht nur auf inflammatorischer, sondern auch auf 
physiologischer Ebene nachgewiesen. Ein anderer therapeutischer Ansatz, mit dem 
ebenfalls anti-inflammatorisch wirksamen Chinin, konnte den Lungenschaden in diesem 
Modell nicht beeinflussen. 
 
Zusammenfassend lässt sich aussagen, dass die hier etablierte Maus-Intensivstation eine 
protektive Beatmung unter der permanenten Überwachung klinisch relevanter Parameter 
ermöglicht. Dieser Versuchsaufbau eignet sich auf Grund der lebenserhaltenden 
Maßnahmen sowohl für Sepsismodelle als auch für die Erforschung von ALI. Eine 
abschließende Clusteranalyse ließ drei unterschiedliche Schadensmuster von ALI erkennen: 
einen „klassischen“ inflammatorischen Weg sowie zwei entzündungsunabhängige 
Mechanismen, von denen einer mit Atelektasen und der andere mit chemischer Verletzung 
assoziiert war. Diese Ergebnisse deuten darauf hin, dass die klinische Wirksamkeit von anti-
inflammatorischen Medikamenten, wie beispielsweise den Steroiden, von der Ätiologie des 
ALI abhängig ist. 
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1 Introduction 
 
1.1 Anatomy of the human lung 
The respiratory system can be divided into an extra-thoracic tract with nose and larynx and 
an intra-thoracic tract to which the trachea, the bronchi and the lungs belong [1]. The lung 
(pulmo) is a paired organ, comprising a right lung with three lobes and a left lung with two 
lobes (Fig. 1.1). When reaching the hilus of the lung, the trachea bifurcates into a right and a 
left main bronchus of which one enters each lung. The intrapulmonary bronchi further branch 
into three right and two left lobular bronchi with ten segmental bronchi in each lung. The 
bronchi finally split into terminal and respiratory bronchioles which terminate, on average in 
the 23rd generation, in the alveoli. The air conducting part of the respiratory system is the 
anatomical dead space of the lung (~150 mL). The respiratory bronchioles divide into two 
alveolar ducts that end in alveolar sacs, were the gas exchange takes place. Each terminal 
bronchiole carries about 200 alveoli, which comprise one morphological unit called acinus. 5-
10 acinini form one lobulus, a unit with about 1 mL gas volume. The total lung capacity of the 
human lung is about 5 L, whereof about 0.5 L is the average tidal volume [2]. The lobuli form 
bronchopulmonal segments, of which the right lung has ten and the left mostly only nine. 
Each segment is supplied with a segmental bronchus and a furcation of the arteria 
pulmonalis. The alveoli are covered by a dense capillary network (vasa publica), containing 
about 200 mL of blood that is involved in gas exchange on a surface area of about 140 m2. 
Gas exchange takes place by diffusion over the alveolar-capillary barrier, a thin layer of only 
2 µm, which consists of alveolar epithelial pneumocytes type I, an interstitial space and 
vascular endothelial cells [3]. Besides of the pneumocytes type I, also the surfactant 
producing epithelial pneumocytes type II, non-ciliated bronchiolar clara cells and alveolar 
macrophages are cell types that are unique to the lung. Beyond these, 40 other types of 
epithelial, connective tissue and blood cells are located in the lung [4]. The nourishment of 
the lung is provided by a second vascular network, the vasa privata. The lung is innervated 
by the plexus pulmonalis containing parasympathetic fibers of the nervus vagus, responsible 
for bronchoconstriction, and fibres of the truncus sympathicus, causing bronchodilatation [5]. 
The innervation is restricted to the peribronchial and perivascular musculature. The primary 
function of the lung is the gas exchange, during which O2 diffuses from the alveoli into the 
blood and CO2 from the blood into the air spaces. In addition, the lung has several other 
important functions e.g. filtration of the blood, synthesis of mucus and surfactant, uptake, 
storage and detoxification of foreign substances, cytochrome p-450 metabolism [6] and 
processing of hormones and vasoactive substances [7,8]. 
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Fig. 1.1: The human lung. A. Right and left lung with right main bronchus (RB) and left main bronchus (LB), 
which derive from the trachea, entering the lungs at the hilus. The bronchial tree with lobular and segmental 
bronchi is projected from ventral on to the lungs. Segmental bronchi are indicated by numbers from 1 to 10. 
B. Terminal respiratory unit consisting of a terminal bronchiole with several respiratory bronchioles. The air 
conducting part ends in the alveoli, where gas exchange takes place. CO2-rich blood, coming from the heart, 
enters the lung via the pulmonary arterioles, gas exchange takes place in the capillary network and O2-rich blood 
leaves the lung via the pulmonary venules. The sum of alveoli derived from one terminal bronchiole is termed 
acinus. Figures are modified according to Sobotta [9]. 
 
 
1.2 Physiology of the lung 
The lung is an elastic structure without own musculature. Each lobe is surrounded by a 
visceral pleura, which has direct contact to the parietal pleura that lines the rib cage. The 
lung follows all movements of the rib cage. Ventilation takes place by movement of the 
diaphragm and the intercostal muscles. Two forces oppose each other during breathing: the 
centripetal retraction of the lung, which is mainly due to the elastic properties of the lung, and 
the centrifugal retraction of the thorax, which depends on the muscle tone of the respiratory 
muscles. The elastic properties of the lung are facilitated by collagen and elastic fibres in the 
walls of the alveoli, bronchioles and capillaries on the one hand and by the phospholipid-rich 
surfactant, which lines the alveoli and prevents alveolar collapse by reducing the alveolar 
surface tension [10,11], on the other hand. During ventilation, air always moves from the high 
to the low pressure area. The driving force is the transpulmonary pressure, which is 
determined by the intra-alveolar pressure minus the subatmospheric pleural pressure, which 
is caused by the recoil of the lung. During inhalation, the thorax is expanded by muscle 
contraction, leading to a passive expansion of the lung, a decrease in the alveolar pressure 
and inflow of air until the alveolar pressure equals the atmospheric pressure. In the 
exhalation phase, the chest cavity becomes smaller by muscle relaxation, the alveolar 
 Introduction  
  3  
pressure increases above the atmospheric pressure and air streams out. The ability of the 
lungs to expand is expressed by the pulmonary compliance (C), which is defined as volume 
change (ΔV) per unit of pressure change (ΔP) across an elastic structure:  
P
VC Δ
Δ=   
The volume-pressure curve is non-linear. C is highest at the residual volume, i.e. the volume 
that remains in the lungs after maximal exhalation, and decreases with increasing lung 
volume. Also, C depends on the size of the lungs. Larger lungs have a higher C than small 
lungs. The measurement of C indicates how easily the lung is inflated and is the inverse 
value of the elastance that indicates the stiffness of the lung [12]. 
Besides of the elastic forces of the lung, which have to be overcome only during inspiration, 
the resistance of the lung plays a role during inspiration and expiration. The pulmonary 
resistance (R) is composed of the airway resistance and to a lesser degree also forces of 
friction in the lung tissue. Pulmonary resistance is defined as pressure change (ΔP) between 
alveolar pressure and atmospheric pressure divided by flow (Vflow): 
flowV
PR Δ=   
About 90% of the airway resistance is due to central and only about 10% to peripheral 
airways. Airway resistance depends on various parameters including the airway calibre, the 
air flow or breathing rate and the type of flow, determined by the size and form of the airway. 
As a result, small airways have a higher resistance than large airways at a constant flow [12].  
 
 
1.3 Assessment of lung mechanics 
One way of describing lung mechanics is inverse modelling i.e. construction of mathematical 
models that predict structural changes, based on experimental measurement of mechanical 
function [13]. In the following only those two models will be discussed that were actually 
applied in this thesis, namely the ’single-compartment model’ and the ’constant phase 
model’. The models are illustrated in Fig. 1.2. 
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Fig. 1.2: Models of the lung. A. Single-compartment model. The lung is described as one compartment formed 
by two telescope canisters, which are connected by an elastic spring representing the tissue properties. The 
airways are described by an open tube. V: volume of the compartment, E: elastance of the spring (E=1/C), R: flow 
resistance, Pel: elastic recoil pressure, ΔP: pressure difference between the ends of the tube. B. Constant-phase 
model. The model is based on the single compartment model, but here the tissue properties are frequency-
independent. G and H: tissue impedance, RN: Newtonian flow resistance, I: gas inertance. The figure is modified 
according to J.H.T. Bates [14].  
 
 
1. The linear first-order single compartment model is a simple model that describes the lung 
as an elastic structure with one compartment, comparable to a balloon, which is filled via a 
stiff tube, which represents the properties of the conducting airways [15]. A slightly modified 
version of the single compartment model is depicted in Fig. 1.2A. Despite of its simplicity, the 
model reflects anatomical and functional aspects of the lung. It can be described by the 
following equation: 
0PC
VRVP flow ++=   
The total pressure across the model from the entrance of the tube to the outside of the 
elastic structure is the sum of the elastic recoil pressure (Pel = V/C) and the pressure 
difference between the ends of the tubing (ΔP = VflowR) plus the positive-endexpiratory 
pressure (P0) that keeps the lung open [14]. Fitting the airway opening pressure and flow 
measured in a subject to this model allows calculation of the dynamic resistance and 
compliance.  
 
Another approach, in which the lung is assumed as a linear dynamic system, is the 
calculation of the pulmonary input impedance (Z) [16]. The impedance reflects how difficult it 
is to get a certain quantity through a system. In the lung, the impedance relates flow and 
pressure. The term input derives from the fact that both parameters are measured at the 
same site, the entrance of the lung. To determine Z, a flow (Vflow) is applied to the lung and 
the pressure P is measured. Vflow and P are transformed by a Fourier transformation so that 
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they can be expressed as a function of frequency instead of time, before the impedance is 
calculated [14]: 
)(
)(
fV
fP
flow
=Ζ  
One mode of applying a suitable flow to the lungs is to induce a sine-wave at a specific 
frequency. A more common method, known as the forced oscillation technique (FOT), 
involves application of multiple sinusoidal frequencies at the same time, which are higher 
than the frequency of breathing (< 0.5 Hz) [13,17]. FOT is also relevant in clinical praxis, as it 
can be superimposed on the breathing pattern and allows non-invasive assessment of lung 
functions [18,19]. 
 
2. A more advanced model of the lung is the constant phase model, in which the tissue 
component is independent of frequency and therefore constant, which is not the case in the 
single compartment model (Fig. 1.2B) [20]. Assessing the impedance by FOT, followed by 
constant phase analysis is a method that reveals accurate impedance data even in mice in 
which the small size and low air flow hinder other methods of lung function measurement 
[15,21]. A frequency spectra < 20 Hz was found to result in precise fits for the impedance 
also in several other species [22,23]. The input impedance of the constant phase model is 
described with the following equation [20]: 
αωω
iHGIiRN
−++=Ζ   and  
G
H1tan2 −= πα  
(Z: pulmonary input impedance; RN: Newtonian resistance; i = √-1: imaginary unit; ω = 2 π f: 
angular frequency, I: inertance, G: tissue damping, H: tissue elastance) 
 
The impedance has a so called real part (RN), which strongly resembles the resistance in the 
central airways (Raw) [21], and an imaginary part, which describes the tissue component, 
comprising a dissipative part (G: tissue damping) and an elastic part (H: tissue elastance) 
(Fig. 1.2B) [24]. The imaginary part, also termed reactance, results from breathing and 
depends on the the elasticity of the lung. The ratio G/H is termed hysteresivity (η) and 
describes the relation between the dissipated and the stored energy. [25]. Although 
hysteresivity was shown to be relatively constant in one individual, it is discussed that an 
increase in hysteresivity accounts for structural heterogeneity in the lungs, as it increases 
with bronchoconstriction [26,27]. The advantage of fitting the constant phase model to the 
input impedance of the lung is that it allows to distinguish between central and peripheral 
respiratory mechanics [28]. 
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1.4 Acute lung injury and acute respiratory distress syndrome 
Acute respiratory distress syndrome (ARDS) is a life threatening heterogeneous lung disease 
that was first described in 1967, when the use of mechanical ventilation was rare [29]. In 
1994 the American-European Consensus Conference (AECC) on ARDS defined four criteria, 
on which the diagnosis is based to date (Table 1.1). In this definition ARDS is distinguished 
from the less severe acute lung injury (ALI). The criteria include acute onset, bilateral chest 
infiltrates, pulmonary arterial occlusion pressure ≤ 18 mmHg or lack of evidence for 
cardiogenic oedema and a Horovitz index (pO2/FiO2) ≤ 200 mmHg for ARDS and 
≤ 300 mmHg for ALI, respectively [30]. According to a cohort study including over 1000 
patients in the USA, ALI has an incidence of 79 per 100,000 with a mortality around 40%. Of 
the patients with ALI who were ventilated for more than 24 hours, 21% developed ARDS 
[31], demonstrating that ALI has a progressive character. ARDS patients are at high risk of 
developing multiple organ failure, which is the predominant cause of death in ARDS [32,33]. 
 
Table 1.1: Clinical and experimental criteria for ARDS and ALI 
Criterion Clinical Experimental 
Timing Acute onset Acute onset 
Oedema / inflammation Radiograph: bilateral chest infiltrates Histological evidence 
Inflammatory response  
Type of oedema Non-cardiogenic Alterations of the alveolar capillary barrier 
Oxygenation PaO2/FiO2 ≤ 200 mmHg (ARDS) 
PaO2/FiO2 ≤ 300 mmHg (ALI) 
Physiological dysfunction 
 
Clinical criteria according to the American-European consensus conference on ARDS in 1994 [30]. Experimental 
criteria were suggested by the American Thoracic Society workshop report in 2011 [34].  
 
 
In addition to defining ARDS, the AECC distinguished pulmonary ARDS, caused by insults 
directly affecting the lung parenchyma e.g. pneumonia, gastric aspiration or inhalation, from 
extra-pulmonary ARDS, resulting from an acute systemic inflammatory response such as 
sepsis or trauma [30]. Clinically, direct ARDS is characterised by a stronger increase in lung 
elastance and appears more resistant to therapeutic interventions, e.g. positive end-
expiratory pressure (PEEP), prone positioning or recruitment manoeuvres than indirect 
ARDS [35]. 
 
Therapeutic approaches in ARDS are restricted mainly to supportive care, involving 
mechanical ventilation (MV). Although MV is mandatory in ARDS patients, it bears the risk of 
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inducing and worsening lung injury, especially in the typically inhomogeneously damaged 
ARDS lungs, a well characterised process termed ventilator-induced lung injury (VILI) [36-
38]. The only clinical intervention that resulted in significant improvement of mortality, shown 
in a phase III trial, was reduction of tidal volume (VT) from 12 mL/kg to 6 mL/kg [39]. The 
effectiveness of pharmacological treatments, e.g. inhaled NO or corticosteroids, lacks 
sufficient clinical evidence [40]. Though steroids are potent anti-inflammatory drugs in 
general, steroid-therapy of ARDS patients resulted in diverse clinical outcome [41,42]. 
However, a beneficial effect of steroids in ARDS is indicated by some clinical studies, 
especially when given in the later fibrotic phase [43,44]. The development of novel effective 
therapies is an important objective in current research, with a special focus on the molecular 
mechanisms that underlie the pulmonary inflammation involved in ALI/ARDS [45]. 
 
 
1.5 Animal models of acute lung injury 
The basis for the development of novel therapies is a better understanding of the complex 
pathomechanisms that lead to ALI/ARDS. For this purpose, animal models are 
indispensable. One difficulty with animal models of ALI is that they do not show exactly the 
same features as the human respiratory failure, although they are based on typical risk 
factors of ALI [46]. Considering the different aetiologies of ALI, one approach to find new 
therapeutic targets is searching for molecular mechanisms that are common in different 
animal models. Given the importance of inflammation in the progression of lung injury, it is 
obvious that pro-inflammatory pathways are in the main focus of investigation [47].  
 
A further problem is the definition of ALI in animal models. Well defined criteria are important 
to validate that the model actually works and for evaluation whether tested therapies are 
successful. Of the four criteria applied in humans (Table 1.1), the bilateral infiltration and the 
non-cardiogenic origin of oedema are difficult to assess in the frequently used small 
laboratory animals, i.e. mice and rats. Moreover, not all research laboratories may have 
access to a blood gas analyser for measurement of oxygenation. The question, how to 
standardise ALI in animal models, led to a first definition of ALI in animals by the American 
Thoracic Society [34]. This definition includes the following five experimental criteria for ALI: 
acute onset, histological alterations, inflammatory response, permeability of the alveolar 
capillary barrier and evidence of physiological dysfunction, e.g. hypoxemia as depicted in 
Table 1.1. Of these criteria, acute onset and at least three of the other criteria should be 
fulfilled to determine that ALI has occurred.  
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Finally, the choice of a suitable model and species is crucial, and depends on the 
mechanism under investigation. Species differences, such as the presence or absence of 
pulmonary intravascular macrophages, NO production or genetic variations regarding Toll-
like or chemokine receptors have to be taken into account [46]. Models of ALI should ideally 
be based on the aetiologies that lead to human lung injury and can therefore be classified in 
models of intra- and extra-pulmonary ALI. 
 
 
 
Fig. 1.3: Mechanisms of pulmonary inflammation caused by endotoxin- (LPS), acid- and ventilator-
induced lung injury (VILI). Mediators are released in the lung in response to an insult recruit and activate 
neutrophils, which are provided with specific receptors and kinases that modulate the immune response. 
Activated neutrophils liberate several effectors, which target the alveolar-capillary barrier and cause oedema 
formation. Progressive oedema leads to hypoxemia and may have lethal consequences. Mediators are depicted 
in pink: LTC4/D4: leukotriens C4 and D4; HMBG1: high-mobility group protein B1; IL-8: interleukin-8, MIP-2: 
macrophage inflammatory protein-2, KC: keratinocyte-derived chemokine; IL-6: interleukin-6; TNF: tumour 
necrosis factor; AT I: angiotensin II receptor type I. Polymorphonuclear leukocyte (PMN) receptors are dark blue: 
DARC: Duffy antigen receptor for chemokines; CD49: cluster of differentiation 49; CD18: cluster of differentiation 
18; CXCRC2: CXC chemokine receptor 2. Kinases are shown in orange: JNK: c-Jun terminal kinase; PI3K: 
phosphatidylinositol-3 kinase. Products of PMNs / neutrophils are depicted in light blue: NADPH oxidase; ROS: 
reactive oxygen species; PAF: platelet activating factor; the protease elastase; MMP8: matrix metalloproteinase-
8. Endothelial proteins are green: MLCK: myosin light chain kinase; ICAM: intercellular adhesion molecule. 
Molecules that are not directly related to neutrophils are listed in the grey box: GADD45: growth arrest and DNA 
damage; NFкB: nuclear factor kappa-light-chain-enhancer of activated B cells; TLR4: Toll-like receptor 4; the 
kinase p38; PARP: poly [ADP-ribose] polymerase. 
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1.6 Experimental intra-pulmonary acute lung injury 
Three widely used models of intra-pulmonary ALI are: instillation of bacterial endotoxin 
(biological insult), instillation of acid (chemical insult) and injurious ventilation (mechanical 
insult). In Fig. 1.3 common mechanisms of pulmonary inflammation in response to these 
three stimuli are depicted, illustrating the outcome of a large number of experimental studies 
reviewed recently [47]. The pathway drawn reflects the hierarchical connection between four 
main features of ALI: neutrophils, oedema formation, hypoxemia and mortality. In response 
to the insult, soluble mediators, such as cytokines and chemokines, are liberated. 
Neutrophils interact with these mediators via surface-bound receptors, sequester in the lung 
and release effector molecules, e.g. platelet activating factor (PAF), reactive oxygen species 
(ROS) and elastase. These products damage the alveolar capillary barrier, thereby inducing 
oedema formation and exacerbating lung injury. As a result, oxygenation is increasingly 
impaired finally leading to death. Of these common mechanisms, some may represent 
promising pharmacological targets. In all three models, neutrophils played a central role. 
Therapies directed against neutrophils directly [48-50], CXCR2 chemokine receptors or their 
neutrophil-attracting ligands (IL-8, MIP-2, KC) [51-53] indicated beneficial effects on lung 
injury. Further targets with good prospects were lipid mediators such as leukotrienes 
(LTC4/D4) and PAF. Inactivation of the leukotriene-producing enzyme 5-lipoxygenase as 
well as of PAF-receptors were beneficial regarding all aspects of lung injury [54-56]. In 
comparison, inhibition of angiotensin II receptor (AT I) activation, tumour necrosis factor 
(TNF), and high-mobility group protein B1 (HMGB1) were found to be only moderately 
protective [57-59]. Of note, in most studies summarised in Fig. 1.3, mechanisms leading to 
neutrophil sequestration or oedema formation were in the main focus, rather than 
oxygenation, physiological dysfunction or mortality, which were mostly ignored [47].  
 
 
1.7 Acid-induced lung injury 
In the following, the model of acid-induced lung injury will be characterised more detailed, 
because it was employed in the present thesis. The basis for this model is that gastric 
aspiration, which occurs for instance as complication during anaesthesia, leads to acute 
pneumonitis [60]. The pulmonary consequences of gastric aspiration are related to the 
composition of the gastric content on the one hand, which cotains particles and bacteria, and 
to the acidic pH on the other hand [61]. In one experimental study, the aspiration of 2 mL/kg 
gastric contents at a pH 5.9 induced the same level of injury as pure acid at pH 1.8 [62], 
demonstrating that the pH alone is not the only harmful factor. 
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The severity of acid-induced lung injury depends on the pH and the volume of the instilled 
acid as well as on time. In most experimental studies, a volume of 1-4 mL/kg acid with a pH 
between 1 and 2 is instilled into the lung. Regarding the pH, the margin between a lethal pH 
(< 1.2) and a non-injurious pH (> 2.5) is rather small. In this range, an almost linear dose-
response curve between acid pH and lung permeability can be drawn. Changes in acid 
volume have a certain influence as well, regarding the fact that very small volumes 
≤ 0.5 mL/kg of acid pH 1.5 are only minimally injurious compared to volumes > 1mL/kg [63]. 
 
Concerning the time course, the injury follows a biphasic pathogensis, with a first peak after 
about 1 hour and a second peak after 4 hours. The first peak is characterised by an increase 
in permeability before neutrophils are recruited to the lung and is probably due to a 
physiochemical reaction to the acid. The later phase is characterised by neutrophil infiltration 
and an acute inflammatory response [63], suggesting that the physiochemical injury is 
followed by inflammatory organ damage. In fact, neutrophils were shown to be necessary for 
the full development of lung injury, whereby in the pathogenesis of the second phase, the 
production of serine proteases (e.g. elastase) by neutrophils seems to play a more important 
role than the neutrophil-derived oxygen radicals [50]. The progression of injury was 
examined by electron microscopy of murine tracheas, where acid at pH 1.5 led to 
desquamation of the superficial cell layer with complete loss of ciliated and non-ciliated cells 
between 6 and 48 hours after instillation. Onset of regeneration was observed after 3 days 
and was completed after 7 days [64].  
 
In conclusion, the advantages of this model include that it is based on a clinically relevant 
aetiology and reflects important hallmarks of the pathogenesis of ALI in humans. Regarding 
the technical issues, the model shows a good reproducibility, but the clinical implications of 
the narrow margin between injurious and non-injurious doses are unclear [46]. 
 
 
1.8 Experimental extra-pulmonary acute lung injury 
Models of extra-pulmonary ALI include a variety of indirect insults that are characterised as 
clinically relevant inducers of ALI such as sepsis, trauma, shock, burn injury or mass 
transfusion [65]. Common experimental approaches to trigger the onset of sepsis are the 
intravenous (i.v.) application of endotoxin or bacteria [46,66]. A model that aims to mimic 
bone trauma is based on i.v. injection of oleic acid [67]. These approaches target the 
capillary endothelium rather than the alveolar epithelium, as the stimulus is administered via 
the venous route. Further indirect insults, which resemble known clinical phenomena, are 
pulmonary and non-pulmonary ischemia-reperfusion or peritonitis induced by cecal ligation 
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and puncture. The disadvantage of these models is that they require complex surgery 
[68,69]. All these models of extra-pulmonary ALI have in common that they usually cause 
milder lung injury than the direct insults. In addition, most of the indirect models are 
subjected to a higher biological variability, which can affect reproducibility [46]. 
 
 
1.9 The role of tumour necrosis factor (TNF) in the lung 
TNF was characterised originally as an anti-tumour agent [70], but it became soon clear that 
it plays a pivotal role as pro-inflammatory cytokine in host-defence, acute inflammation and 
apoptosis [71,72]. TNF can be produced by several populations of leukocytes and triggers 
the production of many other pro-inflammatory cytokines and chemokines [73]. As described 
above, sepsis models are commonly used to induce extra-pulmonary ALI (chapter 1.8). 
Interestingly, high levels of TNF were found in response to i.v. endotoxin application [74,75] 
and application of TNF induced similar metabolic responses as endotoxin in humans [76]. 
Experimental studies revealed that i.v. administered TNF causes a lethal depression of the 
systemic circulation, comparable to the cardiovascular collapse in septic shock [77,78]. This 
observation lead to the hypothesis that septic shock is caused by an overwhelming host 
defence reaction that is characterised by production of high amounts of pro-inflammatory 
cytokines, including TNF. A patient trial in 1987 revealed that a fatal outcome of sepsis was 
correlated with high TNF levels [79]. As a consequence of these findings, anti-inflammatory 
strategies were suggested to be salutary in sepsis [80]. The benefit of anti-TNF therapy in 
septic shock was investigated in baboons and later also in mice, which were protected from 
the lethal effects of endotoxin after pre-treatment with an anti-TNF antibody [81,82]. Based 
on the success in animal studies, several randomised controlled trials were designed to 
investigate the effectiveness of anti-TNF therapies, of which some even reached phase III. In 
these clinical trials either anti-TNF antibodies or soluble receptors were used to inhibit TNF in 
sepsis patients. In several anti-TNF antibody trials this therapy had a small beneficial effect 
on mortality [80,83]. In one phase II trial, using an anti-TNF antigen binding fragment, 
mortality was reduced and the number of ventilator- and intensive care unit (ICU) -free days 
was increased [84]. Furthermore, high IL-6 levels, which correlated with a fatal outcome, 
were reduced by anti-TNF antibodies in several studies [84-86]. Of note, treatment with 
soluble TNF receptors increased mortality in three trials, especially at high doses [80].  
 
TNF plays an important role in the pathogenesis of many pulmonary diseases. Increased 
TNF levels were found in bronchopulmonary secretions of patients with ARDS [87]. 
Persistently high levels of the cytokines TNF, IL-6, IL-1 and IL-8 in the BAL of ARDS patients 
correlated with a poor outcome [88]. In models of intra-pulmonary lung injury, TNF was 
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relateded to neutrophil-dependent mechanisms that promote oedema formation [89,90], as 
indicated in Fig. 1.3. Blocking of TNF by antibodies, receptor-knockout and soluble TNF 
fusion protein, was beneficial in these models [57,91,92]. Only few studies examined the 
pulmonary effects of i.v. injected TNF. In sheep, infusion of 0.01 mg/kg human recombinant 
TNF over 30 min resulted in a pathophysiology comparable to endotoxin-induced lung injury 
[93]. In a study in rats, infusion of 0.1 mg/kg/day human recombinant TNF for 5 days resulted 
in 20% mortality and an increase in lung weight by 38%, although no effect on microvascular 
permeability was found [94]. Of note, TNF doses were fairly low in both studies and little is 
known about the effects of high plasma levels of TNF on the lung in vivo. 
 
TNF interacts with two cell-surface receptors, of which p55 is expressed in most tissues and 
p75 only on cells of the immune system [95]. The receptor p55 appears to promote oedema 
formation by reducing the expression of subunits of the epithelial sodium channel ENaC, 
which is responsible for epithelial sodium transport, the driving force for fluid removal [96]. 
Further, TNF promotes oedema formation by neutrophil-dependent mechanisms that target 
the vascular endothelium. The interaction of neutrophils with the endothelium via the integrin 
complex CD11/CD18 and the endothelial intercellular adhesion molecule 1 (ICAM-1) is a 
prerequisite for neutrophil-related oedema [97]. In experiments with isolated perfused lungs, 
TNF caused oedema formation only, when neutrophils were also added to the lungs [90]. 
This mechanism was shown to be PAF dependent [98] and illustrates why PAF alone 
induces pulmonary oedema in isolated perfused lungs [99], but TNF alone does not. In 
addition, some mechanisms affect the endothelium directly, as shown in experiments with 
endothelial cells in vitro. These include the generation of ROS from endothelial mitochondria 
in response to TNF exposure [100], a mechanism that was shown to involve ceramide [101], 
the structural reorganisation of the endothelial monolayer and the cytostatic effect of TNF on 
endothelial cells [102]. 
 
In contrast to the p55 receptor, p75 seems to have a protective role in the lung [103]. The 
dual role of TNF in pulmonary oedema can be attributed not only to the two receptors, but 
also to the structure of TNF. The cytokine is comprised of a receptor-binding domain that is 
involved in the development of pulmonary oedema and a lectin-like domain, that is distinct 
from the receptor-binding site and has positive effects on alveolar liquid clearance [73]. The 
TIP peptide, a synthetic circular 17 amino acid peptide mimicking the lectin-like domain, 
increases oedema reabsorption by up-regulation of sodium uptake in type II pneumocytes 
and furthermore protects the alveolar barrier integrity by unknown mechanisms. Several 
experimental studies indicate a therapeutic use of the TIP peptide in pulmonary oedema [96]. 
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1.10 The role of sphingolipids in the lung 
Apart from their structural function in cell membranes, sphingolipids exert an important 
function as signalling molecules. Sphingolipids are implicated in the pathogenesis of several 
respiratory diseases including chronic obstructive pulmonary disease (COPD), cystic fibrosis, 
asthma and ALI [104] Particularly the alveolar-capillary barrier integrity is regulated by 
sphingolipids, wherein also TNF plays a role. Apparently, one mechanism leading to ENaC 
inhibition depends on the activation of ceramide by TNF [105]. By binding to p55, TNF 
activates the neutral and the acid sphingomyelinase, enzymes that hydrolyse the membrane 
protein sphingomyelin into ceramide [106,107], which forms lipid microdomains. Ceramide is 
a signalling molecule that acts on several protein kinases, e.g. the protein kinase C (PKC) 
[108], which regulates ENaC activity [109]. A further TNF-induced pathway includes 
activation of the endothelial nitric oxide synthase (eNOS) via the neutral sphingomyelinase 
and the kinases PI3K and Akt [110,111]. This pathway links ceramide production to 
vasodilatation via NO liberation [112]. Of note, eNOS also plays a crucial role in regulation of 
pulmonary vascular permeability, as both too little and too much NO can cause pulmonary 
oedema [99]. 
 
The acid sphingomyelinase (ASM) appears in a lysosomal and a secretory form [113]. The 
secretory form, which hydrolyses sphingomyelin in the cell membrane, has been associated 
with the pathogenesis of sepsis and ALI. Patients with sepsis exhibited increased levels of 
ASM activity, which correlated with mortality [114]. One proposed mechanism involving the 
lysosomal ASM implies that caveolin-1 is recruited to the ceramide-rich domains (caveolae) 
formed by ASM, through which endothelial NO is decreased and endothelial Ca2+ is 
increased, promoting pulmonary oedema [99]. The physiologic importance of ASM is further 
demonstrated by the consequences of ASM-deficiency, which is responsible for a recessively 
inherited lysosomal lipid storage disorder called Niemann-Pick disease (NPD) type A and B. 
Type A NPD is a neurovisceral form leading to early death in childhood, whereas type B NPD 
is a non-neuropathic, visceral form with a longer life expectancy [115]. ASM-deficiency is 
caused by mutations in the SMPD1 gene. The pathophysiology of NPD is characterised by 
the accumulation of sphingomyelin and other lipids, causing cell abnormalities which lead to 
visceral organ complications, including progressive pulmonary dysfunction with repetitive 
respiratory infections [116]. Experimentally, ASM-deficient (ASM-/-) mice were shown to be a 
valuable tool for the investigation of the important role of the ASM in sepsis and ALI. In 
endotoxemia and in models of intra-pulmonary ALI, pharmacological blocking of ASM and 
ASM-deficiency protected from vascular barrier disruption [117-119] and reduced mortality 
due to septic shock [114,117]. These findings indicate that ASM may be another interesting 
therapeutic target for the treatment of ALI [104], particularly in conjunction with sepsis.  
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Finally, the generation of ceramide by ASM in the caveolae was also shown to be involved in 
apoptosis [120]. Interestingly, ceramide activates not only the well-known caspase-
dependent pathway, but also a caspase-independent mechanism. Whereas caspase-
dependent extrinsic apoptosis is induced by ligands that bind to so called death receptors, 
e.g. TNF and p55, the caspase-independent pathway is proposed to be predominantly 
stress-induced, e.g. by UV radiation [121-123]. This was also shown in vivo in ASM-/- mice, 
which were protected from radiation-induced ceramide-generation and apoptosis [124]. 
Nevertheless, formation of ceramide by ASM was also shown in response to TNF, resulting 
in activation of the transcription factor NFкB, one important regulator of apoptosis [107]. 
Furthermore, enzymatic degradation of ceramide and inhibition of ASM were shown to 
increase cell survival in TNF-treated cells [125], indicating a pivotal role of ASM in TNF-
induced cell death. 
 
 
1.11 Mechanical ventilation in mice 
MV of mice is increasingly used in biomedical research. While the mechanisms of VILI have 
been explored intensively [37], experimental conditions required to keep physiological 
parameters stable in mice during ventilation for several hours are not well defined. Major 
reasons for this are the focus on the mechanisms of VILI and the lack of comprehensive 
monitoring of pulmonary and cardiovascular key parameters in most studies. 
 
Monitoring of key physiological parameters is standard during MV of humans and should be 
aimed also in experimental research. These key parameters need to reflect both the 
pulmonary (e.g. VT, airway pressure) and the cardiovascular (e.g. heart rate, blood pressure) 
consequences of MV as well as oxygenation and acid-base status. Although MV may affect 
all these parameters, these entities have rarely been assessed together in the same study in 
mice. Table 1.2 summarises ventilation studies, in which either lung impedance was 
measured or ventilation was performed for at least four hours. The table reveals that many 
studies that have focused on lung mechanics examined only a relatively short period of 
ventilation [126-129] and only one study fulfilled both inclusion criteria [48]. Interestingly, 
studies in which mice were ventilated for more than three hours often provided 
cardiovascular parameters, but neglected the examination of lung functions [130-133]. Some 
studies even completely lacked physiological parameters, although in several cases the 
authors referred to preliminary experiments that were not included in the published data 
[134-137]. Thus, without comprehensive information on physiological parameters, it seems 
difficult to properly assess, standardise and compare the various ventilation strategies.  
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Table 1.2: Comparison of mouse ventilation models 
Reference Experimental design Monitored parameters 
 Ventilation VT [ml/kg] PEEP [cmH2O] RM 
Lung 
functions BGA 
BP / cardiac 
activity SpO2 
[126] 30min 7 / 10 2 / 0 * + - - / P + 
[128] 60min 8 6 / 3 ** + - - - 
[129] 140min 30 / 10 2 / 0 2x / min + + - / ECG - 
[127] 150min 8 6 / 2 1x / 5min or 1x / 75min + - - / P + 
[48] 4h 25 / 7 - - + - - / ECG - 
[134] 4h 20 / 6 2 - - - - - 
[137] 4h 30 - - - - - - 
[135] 4h 20 / 7 0-2 - - - - - 
[132] 4h 8 4 - - + + / - - 
[136] 5h 30 / 6 - - - - - / - - 
[133] 5h 15 / 7.5 2 - - + + / + - 
[53] 6h 24 - - - - + / P - 
[130] 6h 12 6 * - + + / P + 
[138] 4h / 8h 20 / 10 2 1x / h - - + / - - 
[131] 8h 12 2 - - + + / - - 
Present 
study 6h 16 / 8 2 
1x / 5min or 
1x / 60min 
or no RM 
+ + + / ECG, P + 
 
The table lists those ventilation studies that analysed lung functions by measurement of lung impedance and 
studies in which mice were ventilated for at least four hours. VT: tidal volume, PEEP: positive end-expiratory 
pressure, RM: recruitment manoeuvre, BGA: blood gas analysis, BP: blood pressure, P: pulse, ECG: 
electrocardiogram, SpO2: pulse oximetry. * One RM at the beginning of ventilation. ** Two RM at the beginning 
of ventilation. 
 
 
Studies on the mechanisms of VILI have identified several beneficial ventilation strategies, 
among them low VT ventilation and application of recruitment manoeuvres (RM) as well as 
high PEEP. Although RM have a sound physiological basis, it remains unclear how they 
should be applied [139]. In principal, RM may be used to reopen atelectatic lung areas in 
injured lungs or to prevent atelectasis in healthy lungs. The latter application requires lower 
recruitment pressures and hence can be applied more frequently. Without RM, pulmonary 
compliance is likely to decrease as shown already many years ago in anaesthetised dogs 
both during spontaneous breathing and during MV [140]. In addition, regular short RM have 
proved to be useful in models of isolated rat and mouse lungs [141,142]. In mechanically 
ventilated mice the usefulness of RM with the specific aim to keep pulmonary compliance 
and other lung functions constant has been explored only sporadically. Previous RM studies 
in healthy mice have focused on short periods of ventilation and potential lung injury, but did 
not compare ventilation with and without RM over several hours [127,129]. Further, the effect 
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of RM on blood pressure in mice is not well defined, although increased intrathoracic 
pressure might decrease cardiac output [143]. The beneficial effects of PEEP have been 
demonstrated in several animal studies [144-146]. PEEP helps to prevent repetitive alveolar 
collapse and preserves surfactant function [37,147]. While it is widely accepted that 
adequate PEEP together with low VT is a protective ventilation strategy, the effects of 
recurrent RM in this setting are unknown. 
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1.12 Aim of the study 
ALI is a life threatening condition, for which to date only symptomatic therapy, such as MV, is 
available. Animal models are indispensable to elucidate the pathomechanisms of ALI and to 
develop therapeutic approaches. MV of mice is increasingly used in experimental studies on 
lung injury, but conditions for ventilation of mice resulting in stable physiological conditions 
are poorly defined. In most studies, monitoring of clinically relevant physiological parameters 
is omitted and validation of pulmonary injury is based on inflammatory parameters only. 
Mouse models of ALI giving comprehensive information on the mechanisms of lung injury 
under consideration of the physiological consequences are largely lacking. 
 
Thus, the first objective is to establish an ’ICU–like’ setup that allows ventilation of mice 
under permanent monitoring of respiratory and cardiovascular parameters and to define 
conditions under which these parameters are stable over several hours. Of particular interest 
is the impact of recurrent RM at different VT and PEEP levels. While it is widely accepted that 
adequate PEEP together with low VT is a protective ventilation strategy, the effects of 
recurrent RM in this setting are unknown. Furthermore, pulmonary inflammation should be 
assessed by quantifying microvascular permeability, neutrophil recruitment to the lung, pro-
inflammatory mediators and a lung injury score, in order to identify the most protective 
ventilation strategy. Altogether, the setup should include all relevant criteria for the diagnosis 
of experimental ALI, so that it can be employed as basis for lung injury models. 
 
This mouse ICU should then be used to examine the unexplored effects of high systemic 
TNF levels on the lung. TNF plays a major role as mediator of sepsis and ALI and high 
systemic levels might even cause lung injury. A setup that provides life supportive measures 
ought to be suitable to avoid lethal the cardiovascular depression, a TNF-related side effect 
known from experimental and clinical trials, and allow investigation of the impact of TNF on 
the lung. A further aim is to define the role of ASM and caspases in the TNF-induced 
pathophysiology. 
 
In addition, intra-pulmonary lung injury is planned to be induced by acid-instillation, a model 
that resembles crucial features of ALI in humans. Based on the experimental criteria of ALI, 
the therapeutic effectiveness of the glucocorticoid dexamethasone should be tested. The 
usefulness of steroids in ALI is still under debate, since the outcome in clinical studies is 
inconclusive and experimental studies lack information on the physiological consequences. 
This part of the study aims to provide further insight into the complex role of steroids in ALI 
by taking the severity of lung injury into account. A final objective is to analyse the injury 
models for possible pathophysiological patterns in ALI. 
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2 Material and methods 
 
2.1 Mice 
Ventilation and acid-instillation experiments were performed with female C57BL/6 N mice 
(Charles River, Sulzfeld, Germany) aged 8 to 12 weeks, weighing 20 to 25 grams. The 
effects of TNF were investigated in female and male C57Bl/6x129/SvEv wild-type (wt) and 
acid sphingomyelinase-deficient (ASM-/-) mice aged 8 to 10 weeks, weighing 25 to 30 grams, 
kindly provided by Prof. Dieter Adam (Institute of Immunology, Christian Albrechts University, 
Kiel, Germany). The experimental protocols were in accordance with the German animal 
protection law and approved by regional governmental authorities (Landesamt für Natur, 
Umwelt und Verbraucherschutz NRW, permission numbers: AZ 8.87-50.10.35.085 and AZ 
8.87-50.10.37.09.287). 
 
 
2.2 Drugs, chemicals, kits, equipment and software 
2.2.1 Drugs and infusions used for mice 
Bovine serum albumin Serva electrophoresis, Heidelberg, Germany 
Braunol 7.5% B. Braun Melsungen AG, Melsungen, Germany 
Dexamethasone dihydrogen phosphate  Merck Pharma GmbH, Darmstadt, Germany 
Fentanyl Janssen-CILAG GmbH, Neuss, Germany 
Heparin sodium salt Sigma-Aldrich, Dorset, UK 
Human serum albumin Baxter, Unterschleißheim, Germany 
Hypochloric acid solution Merck Pharma GmbH, Darmstadt, Germany 
Ketamine CEVA, Düsseldorf, Germany 
Isoflurane Abbott GmbH & Co. KG, Wiesbaden, Germany 
Isotonic sodium chloride 0.9% B. Braun Melsungen AG, Melsungen, Germany 
Quinine hydrochloride dihydrate Sigma-Aldrich, Steinheim, Germany 
Ringer’s solution B. Braun Melsungen AG, Melsungen, Germany 
Sodium hydrogen carbonate 8.4% Fresenius Kabi  GmbH, Bad Homburg, Germany 
Sodium pentobarbital  Merial GmbH, Hallbergmoos, Germany 
TNF (murine) Peprotech, Rocky Hill, CT, USA 
Xylazine CEVA, Düsseldorf, Germany 
Xylocain 1% AstraZeneca GmbH, Wedel, Germany 
zVAD-fMK Bachem AG, Bubendorf, Switzerland 
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2.2.2 Chemicals 
Chloroform  AppliChem, Darmstadt, Germany 
Diff-Quick staining Medion Diagnostics, Düdingen, CH 
Eosin Merck, Darmstadt, Germany 
Ethanol 70% Otto Fischar GmbH, Saarbrücken, Germany 
H2O2 30% Merck, Darmstadt, Germany 
Methanol AppliChem, Darmstadt, Germany 
Mayers Hämalaun Merck, Darmstadt, Germany 
Roti Histofix 4% Carl Roth GmbH, Karlsruhe, Germany 
Sphingomyelin Sigma-Aldrich, Steinheim, Germany 
TMB substrate reagent R+D Systems, Abingdon, UK 
Tween20 Serva electrophoresis, Heidelberg, Germany 
Vitro-Clud mounting medium Langenbrinck, Emmendingen, Germany 
 
2.2.3 Commercial kits 
BSA ELISA Bethyl Laboratories, Montgomery, USA 
Cell death detection ELISA Roche Applied Science, Mannheim, Germany 
DC Protein assay Bio-Rad, Hercules, CA, USA 
HSA ELISA Assaypro, St. Charles, MO, USA 
IL-6 ELISA R+D Systems, Abingdon, UK 
KC ELISA R+D Systems, Abingdon, UK 
MIP-2 ELISA R+D Systems, Abingdon, UK 
NO quantification assay R+D Systems, Abingdon, UK 
Procalcitonin ELISA USCN Life Science, Wuhan, China 
TNF ELISA R+D Systems, Abingdon; UK 
 
2.2.4 Buffers 
Carbonate/bicarbonate buffer (pH 9.4) 2 mL 0.1 M Na2CO3, 8 mL 0.1 M NaHCO3 
Phosphate buffered saline (PBS) 10x  160 mM Na2HPO4, 40 mM NaH2PO4, 1.5 M NaCl 
Potassium phosphate buffer 0.05 M 0.05 M KH2PO4, 0.1 M K2HPO4 (pH = 6) 
Wash buffer for ELISA 0.05% Tween20 in PBS (pH = 7.2-7.4) 
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2.2.5 Equipment 
Blood gas analyser ABL700 Radiometer, Kopenhagen, Denmark 
Blood pressure transducer APT300  Harvard Apparatus, March-Hugstetten, Germany 
Bio amplifier for ECG and lead wires ADInstruments, Spechbach, Germany 
Bridge amplifier for blood pressure ADInstruments, Spechbach, Germany 
Cold-light source Streppel, Wermelskirchen-Tente, Germany 
Cytospin centrifuge and equipment Hereaus, Hanau, Germany 
ELISA Reader GENios Tecan, Männedorf, Switzerland 
FlexiVent ventilator with module 1 SCIREQ, Montreal, Canada 
Homeothermic blanket system Harvard Apparatus, March-Hugstetten, Germany 
Injection needles (Microlance) Beckton Dickinson, Franklin Lakes, NJ, USA 
Mass flow controller 0254 Brooks Instrument, Hatfield, PA, USA 
Micro-Fine+Demi U-100 insulin syringes Beckton Dickinson, Franklin Lakes, NJ, USA 
Microscope Axio Lab Zeiss, Jena, Germany 
Microsprayer Penn-Century Inc., Wyndmoor, PA, USA 
MouseOx pulse oximeter Starr Life Sciences Corp., Oakmont, PA, USA 
Oximeter pod with SpO2 tail wrap ADInstruments, Spechbach, Germany 
PE-10 tubing Beckton Dickinson, Franklin Lakes, NJ, USA 
PowerLab 8/30 data acquisition system ADInstruments, Spechbach, Germany 
Precision Infusion pump 11 Plus Harvard Apparatus, March-Hugstetten, Germany 
Pulse oximeter ADInstruments, Spechbach, Germany 
Surgical micro instruments Fine science tools, North Vancouver, BC, Canada
Sutures Pearsall’s, Taunton, UK 
Thermal mass flow meters Brooks Instrument, Hatfield, PA, USA 
Tygon tubing (0.25 mm inner diameter) Novodirect, Kehl am Rhein, Germany 
Vaporizer + Filter for Isoflurane Harvard Apparatus, March-Hugstetten, Germany 
 
2.2.6 Software 
AxioVision Zeiss,Jena, Germany 
FlexiVent 5.2 SCIREQ, Montreal, Canada 
GraphPad Prism 5.0 GraphPad Prism, La Jolla, CA, USA 
JMP 7.0 SAS Institute, Cary, NC, USA 
LabChart 7.0.2 ADInstruments, Spechbach, Germany 
SAS 9.1 SAS Institute, Cary, NC, USA 
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2.3 Anaesthesia 
2.3.1 Ketamine and xylazine 
In the first experiments, the sedative and analgesic drug ketamine [120 mg/kg], which binds 
amongst others to the glutamate-NMDA-receptor-complex, together with the α-agonist 
xylazine [25 mg/kg], a combination commonly used in rodents, was used for anaesthesia. 
After few experiments only, this combination was found to be inappropriate. These drugs do 
not suppress the CO2-induced breathing reflex so that hypercapnic mice breathe 
spontaneously during ventilation. Hypercapnia can be caused by extreme ventilation settings 
or impaired gas exchange so that this condition appears commonly in models of acute lung 
injury. Since measurement of lung functions with the flexiVent ventilator, which was used in 
this study, requires complete oppression of spontaneous breathing, anaesthesia allowing 
spontaneous breathing was unsuitable for the present study. A further disadvantage was that 
xylazin induced severe bradycardia leading to lethal circulatory failure after about four hours. 
This limited the duration of the experiments, which were planned for at least six hours, 
strongly. Bradycardia could have been antagonised by the vagolytic drug atropine, which 
was considered as unsuitable because of its versatile pharmacological effects, which could 
have influenced the outcome of the lung injury. 
 
2.3.2 Isoflurane 
Next, the volatile anaesthetic isoflurane, which was given in concentrations of 1-3% with a 
vaporizer via the tracheal line after induction of anaesthesia with ketamine and xylazine, was 
tested. Isoflurane was chosen because it is routinely used for anaesthesia in patients and it 
was one aim to establish a setup that resembles the clinical situation as close as possible. 
This drug turned out to be inappropriate for experimental usage in the present setup. Again 
spontaneous breathing impaired the measurement of lung functions. Moreover, it seemed 
very likely that inhaled isoflurane, which has anti-inflammatory properties, could have 
influenced the outcome of the lung injury models. Therefore it was necessary to find other 
more appropriate drugs for long-term anaesthesia. 
 
2.3.3 Pentobarbital sodium and fentanyl 
Anaesthesia with the barbiturate pentobarbital sodium for sedation and the opioid fentanyl as 
analgetic component proved to be adequate for deep sedation and oppression of the 
breathing reflex, which were required for measurement of lung mechanics. A further 
advantage was the inhibition of CO2 chemoreceptors in the brain by pentobarbital sodium, 
which prevented the breathing reflex also in hypercapnic animals. Under barbiturates the 
breathing reflex is solely activated by hypoxia. Therefore it was important to apply not more 
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than maximally 30% of oxygen to mice that were anaesthetized, but not yet connected to the 
ventilator. The additional oxygen was delivered by a gas mixing device and was applied to 
the mouse via a small mask that was placed over the snout. Anaesthesia was initiated with 
an intra-peritoneal injection of pentobarbital sodium [75 mg/kg] and fentanyl [40 µg/kg]. 
Sedated mice were placed in supine position and 50 µL of 1% Xylazin was injected 
subcutaneously above the larynx for local anaesthesia. This reduced the application rate of 
pentobarbital sodium. Anaesthesia was maintained with pentobarbital sodium [20 mg/kg] via 
an intra-peritoneal catheter, made of a 30 gauge needle and a thin Tygon tubing, every 30 to 
60 minutes. The fractionated administration of the barbiturate resulted in stable 
cardiovascular parameters. The disadvantage of pentobarbital is the narrow therapeutic 
index, which comprises a risk of lethal overdosing. A further advantage is that pentobarbital 
and fentanyl do not interfere with inflammatory pathways. 
 
 
2.4 Tracheotomy 
After verifying sufficient sedation by checking the paw withdrawal reflex, the fur on the throat 
of the mouse was disinfected with an ethanol-free iodide solution and opened with a 
longitudinal cut above the trachea. The left and right musculi sternocleidomastoidei were 
pulled apart to expose the trachea. The muscule strand surrounding the trachea (musculus 
sternohyoidus) was cut open and a suture was pulled around the trachea to form a loose 
ligature. The trachea was opened by a small cut through which a 20-gauge cannula was 
inserted and fixed by tightening the ligature. The cannula was coupled with a short piece of 
plastic tubing that served as adaptor for connection to the ventilator. The length of this 
adaptor was varied to increase dead space, if necessary. 
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2.5 Mechanical ventilation and measurement of lung functions 
After tracheotomy, mice were ventilated with the flexiVent ventilator, a computer controlled 
piston-stroke ventilator that facilitates the measurement of lung mechanics by the low 
frequency FOT. The ventilator operates volume controlled and is equipped with a piston that 
moves in a closed glass cylinder, and two magnetically controlled valves (Fig. 2.1). The 
inspiratory valve was connected to the gas mixing device and opened during the inspiration 
period. A Y-Piece connected the tracheal cannula with the inspiratory valve and the 
expiratory valve via inflexible tubing. The expiration valve opened after closure of the 
inspiration valve to allow the release of the inhaled gas. A PEEP trap, in form of a simple 
water column which could be varied as necessary, was attached to the expiratory valve. The 
tubing connecting the Y-piece with the expiratory valve was interrupted by a pressure 
transducer (P1). A second pressure transducer (P2) was located behind the expiratory valve. 
 
 
 
Fig. 2.1: Ventilation setup. Ventilation was performed with a computer-controlled piston stroke ventilator. Mice 
were connected to the ventilator with a tracheal cannula attached to a Y-piece, which facilitated the connection to 
the inspiratory and the expiratory valve. The gas supply was coupled to the inspiratory valve with a tubing that 
carried one open end, used as oxygen mask, for overpressure relief. A PEEP trap was attached to the expiratory 
valve. The ventilator was equipped with two pressure transducers (P1 and P2), allowing flow measurement. P1 
was located at the cylinder, in which the piston moved, and P2 in the expiration branch. 
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The flexiVent measures the volume displaced by the piston and the pressure in the cylinder 
from which the mechanical load presented by the lungs of the mouse is calculated. 
Calibration of the system prior to each experiment allowed subtracting the load of the 
ventilator and the tubing from the load of the lungs facilitating accurate calculation of lung 
mechanics. The measurement of lung mechanics with the flexiVent is based on the FOT, 
which interrupts the ventilation mode and induces a low frequency oscillatory waveform to 
the respiratory system. Two different types of oscillatory measurements were performed with 
the flexiVent: firstly, a perturbation that included one single-frequency sinusoidal waveform, 
from which the dynamic resistance (R) and compliance (C) were calculated according to the 
single compartment model; secondly, a multi-frequency oscillation waveform for 
measurement of the input impedance at different frequencies. Fitting the constant phase 
model to the impedance allowed differentiating between the mechanics of the central airways 
and the periphery of the lung. The resulting parameters were: airway resistance (Raw), tissue 
elastance (H) and tissue damping (G). Ventilation settings are described in chapter 2.7. 
 
 
2.6 Monitoring of physiological parameters 
In order to monitor the general health condition of the mice, several physiological parameters 
were measured during ventilation. Fig. 2.2 shows an overview of a mouse connected to the 
ventilator and several measuring instruments, which are explained in detail below. 
 
 
 
Fig. 2.2: Overview: mouse during physiological monitoring. The mouse was positioned on a body-
temperature controlled heating blanket. Body temperature was measured with a rectal probe. A clip with a 
photosensor for pulse oximetry was attached to the tail. ECG leads were inserted with thin needles 
subcutaneously at the paws. A catheter was placed intra-peritoneally for maintenance of anaesthesia. A further 
catheter was inserted into the carotid artery for blood pressure measurement and fluid supply. The mouse was 
ventilated via an intra-tracheal cannula to which an exchangeable adaptor was coupled, with which dead space 
was varied. 
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2.6.1 Body temperature 
Measurement and regulation of body temperature was started immediately after sedation by 
using a homeothermic blanket system in order to avoid hypothermia. The system comprises 
a heated blanket, on which the mouse was placed, a rectal thermometer, to determine the 
temperature of the mouse, and a temperature control system on which the set-point value for 
the body temperature was adjusted to 37°C. The control system turns on the heating of the 
blanket whenever the measured body temperature is below the set-point. In cases of 
hypothermia below 36°C the mouse was additionally warmed by an infrared light to achieve a 
quicker stabilisation of the body temperature. 
 
2.6.2 Pulse oximetry 
Oxygen saturation was measured with the MouseOx pulse oximeter. The measurement was 
performed with a clip placed on the upper end of the tail. The clip comprises a red and an 
infrared light and as well as a photo sensor. The absorption of light by haemoglobin changes 
upon binding of oxygen, so that the oxygenation level is reflected by the absorption of light. 
In arteries, the light absorption measured by the oximeter oscillates with the cardiac pulse. 
Thereby, not only oxygenation, but also the heart rate can be determined by this device. The 
MouseOx is designed to detect the high-frequency pulse in mice, which is the precondition 
for a reliable measurement. Measurement of oxygen saturation with an oximeter pod 
designed for subjects (ADInstruments, Spechbach,Germany) with a slower pulse failed. 
Oxygenation was monitored throughout the ventilation experiments. 
 
2.6.3 Electrocardiogram and heart frequency 
Electrocardiogram (ECG) was derived from two thin needles, which were used as leads, in 
the paws of the mouse. A third needle was used as ground wire. The needles were 
connected to an bio amplifier and the Powerlab data acquisition system, which was used to 
monitor and record the cardiovascular parameters. Heart rate was calculated from the ECG 
by the LabChart software, which runs the Powerlab system. ECG and heart rate were used 
to evaluate the depth of anaesthesia. 
 
2.6.4 Invasive blood pressure measurement 
For the invasive blood pressure measurement, a catheter was built by connecting one end of 
a 15 cm long polyethylene-10 tubing to the blunt end of a dismantled 27 gauge injection 
needle and the other end to the sharp side of a complete 27 gauge injection cannula. The 
needle shield of the cannula was coupled on a three-way valve, which was also connected to 
an infusion pump and a pressure transducer (APT300). The whole system was filled with 
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either 0.9% NaCl, in the ventilation and TNF model, or Ringer’s buffer, in the acid model. The 
pressure transducer was connected to a bridge amplifier, which was part of the Powerlab 
data acquisition system. About 1 cm of the common carotid artery was exposed below the 
bifurcation into internal and external carotid artery by carefully dissecting the overlying and 
surrounding connective tissue. A thin suture (USP 7-0) was passed under the artery and a 
ligature was placed directly below the bifurcation (Fig. 2.3A). A vascular micro clamp was 
positioned 1 cm proximally from the ligature to occlude the vessel temporarily (Fig. 2.3B). A 
second thread was placed around the artery. Then an incision was made with micro scissors 
through which the catheter was inserted before it was fixated with the second thread 
(Fig. 2.3C). The micro clamp was removed and the infusion pump was started at a rate of 
200 µL/h. The infusion kept the catheter free of blood and supplied the animal with fluid. 
Mean arterial pressure was measured every 10 minutes by closing the three-way valve in 
direction of the infusion by which the valve directed to the pressure transducer was opened. 
 
 
Fig. 2.3: Insertion of the intra-arterial catheter. A. The right carotid artery was exposed and ligature 1 was 
positioned in cranial direction. B. A vascular clamp occluded the blood flow temporarily, while a small incision was 
made. C. The catheter was inserted and fixated with a ligature 2. 
 
 
2.6.5 Injection of albumin for determination of microvascular permeability 
Either 1 mg bovine serum albumin (BSA) or human serum albumin (HSA) was injected i.v. 
during ventilation in all mice. In the ventilation experiments, mice received BSA in 100 µL 
NaCl 90 min prior to exsanguination. In the TNF experiments, BSA was injected in 140 µL 
volume 300 min before the end of the experiment, either together with zVAD-fmk or alone. A 
later injection with additional fluid would have manipulated the experimental design in this 
model. In the acid study, BSA was replaced by HSA, which was injected again 90 min before 
exsanguination. Albumin levels were quantified using commercially available ELISA kits. The 
albumin influx was calculated as follows: albuminBAL / albuminSerum x 1000. 
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2.6.6 Exsanguination and blood gas analysis 
After ventilation, mice were sacrificed by exsanguination via the carotid artery by removing 
the arterial catheter. 55 µL of blood were collected immediately, before the death of the 
experimental animal, with a heparinised capillary for analysis of pO2, pCO2, pH, HCO3- and 
standard base excess (SBE) in a blood gas analyzer. This measurement was essential for 
evaluation of the quality of gas exchange in the ventilated mice. Blood gas analysis from 
anaesthetized control mice was not representative due to reduced breathing activity and was 
therefore omitted. The remaining blood, about 1 mL in most cases, was collected in a 
heparinised tube. The blood samples were centrifuged for 10 min at 3500 rpm to separate 
the blood cells from the plasma, which was collected and snap frozen for quantification of 
cytokines, albumin and other mediators, depending on the model. 
 
 
2.7 Mouse models 
2.7.1 The ventilation model 
For the ventilation model, mice were anaesthetised as described in chapter 2.3 and then 
ventilated for six hours either with low tidal volume (lowVT) of 8 mL/kg and a frequency (f) of 
180 min-1 or high tidal volume (highVT) of 16 mL/kg and f = 90 min-1, so that both groups 
received the same minute volume. The highVT group was ventilated with 3% CO2 to maintain 
normocapnia without further decreasing ventilation frequency or increasing dead space. The 
fraction of inspired oxygen (FiO2) was 0.5 in this model. One RM with 30 cmH2O pressure 
and six seconds duration was performed after onset of ventilation to open airspaces and 
standardise lung volume. Resistance, compliance and impedance of the lung were measured 
during single and multi-frequency oscillation waveforms every ten minutes. In this model, two 
independent series of experiments were performed and analysed separately. The first series 
of experiments was performed with a PEEP of 2 cmH2O. Repeated RM of 1 s duration and 
30 cmH2O peak pressure were applied every five minutes (RM5) in one lowVT (lowVTRM5) 
and one highVT group (highVTRM5) or every 60 minutes (RM60) in one lowVT group 
(lowVTRM60). One lowVT and one highVT group were ventilated without RM (lowVTnoRM and 
highVTnoRM). One group of anaesthetised unventilated mice served as control. In order to 
investigate the effects of a higher PEEP, a second series of experiments was performed 
later, in which mice were ventilated with a low VT and a PEEP of 6 cmH2O. With these 
settings, RM were performed every five minutes (PEEP6_RM5), every 60 minutes 
(PEEP6_RM60) or not at all (PEEP6_noRM). An overview over the experimental groups is 
given in Table 2.1 below. 
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Table 2.1: Experimental groups in the ventilation model 
 Low PEEP (2 cmH2O) Moderate PEEP (6 cmH2O) 
 LowVT RM5 
HighVT 
RM5 
LowVT 
noRM 
HighVT 
noRM 
LowVT 
RM60 
PEEP6 
_RM5 
PEEP6 
_noRM 
PEEP6 
_RM60 
VT [ml/kg] 8 16 8 16 8 8 8 8 
f [min-1] 180 90 180 90 180 180 180 180 
PEEP [cmH2O] 2 2 2 2 2 6 6 6 
RM/h 12 12 - - 1 12 - 1 
FiO2 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
CO2 [%] 0 3 0 3 0 0 0 0 
 
VT: tidal volume, f: breathing frequency, PEEP: positive end-expiratory pressure, RM: recruitment manoeuvre 
of 1 s and 30 cmH2O pressure, FiO2: fraction of inspired oxygen, lowVT: low tidal volume, highVT: high tidal 
volume, RM5: one recruitment manoeuvre every five minutes, noRM: no recruitment manoeuvres, RM60: one 
recruitment manoeuvre every 60 minutes, PEEP6: PEEP = 6 cmH2O.  
 
 
2.7.2 The TNF model 
All mice were ventilated for 30 min to gain stable baseline lung functions. ASM-/- and wt mice 
received 50 µg of murine TNF in 100 µL of 0.9% NaCl i.v. 45 min after onset of ventilation. In 
addition, half of the animals were treated with two i.v. dosages of the general caspase 
inhibitor Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (zVAD-fmk). 
250 µg zVAD-fmk were given in 100 µL of 0.9% NaCl after 30 min of ventilation and 100 µg 
zVAD-fmk together with 1 mg BSA (for analysis of microvascular permeability) in 140 µL of 
0.9% NaCl after 60 min of ventilation. Mice that were not treated with TNF and/or zVAD-fmk 
received comparable volumes of NaCl. All i.v. injections were placed in the tail veins. Mice 
were ventilated for further six hours after injection of TNF, resulting in 405 min total 
ventilation time. The experimental design is depicted in Fig. 2.4 below. 
 
 
Fig. 2.4: Experimental design in the TNF model. TNF was injected 45 min after onset of ventilation to ensure 
stable physiological base line values. Mice were then ventilated for further 6 h. Half of the TNF-treated mice 
received one dose of the caspase inhibitor zVAD-fmk 15 min before and one 60 min after TNF treatment. All 
injections were administered into the tail vain.  
 
Experimental groups, as listed in Table 2.2, were named as follows: mice treated with TNF, 
but not zVAD-fmk: ASM-/--zVAD and wt-zVAD; mice treated with both, TNF and zVAD-fmk: 
ASM-/-+zVAD and wt+zVAD; one group of ASM-/- mice was ventilated without being treated 
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with TNF or zVAD-fmk to investigate only the influence of the ASM-deficiency on the 
ventilated lung: ASM-/--sham. In all groups in this model, ventilation settings were as follows: 
VT = 8 mL/kg, f = 180 min-1, one RM every 5 min, PEEP = 2 cmH2O and FiO2 = 0.3. 
 
Table 2.2: Experimental groups in the TNF model 
 wt-zVAD wt+zVAD ASM-/--zVAD ASM-/-+zVAD ASM-/--sham 
ASM expression + + - - - 
TNF injection + + + + - 
zVAD-fmk injection - + - + - 
Ventilation 405 min 405 min 405 min 405 min 405 min 
 
ASM: acid sphingomyelinase, TNF: Tumor necrosis factor, zVAD-fmk: Carbobenzoxy-valyl-alanyl-aspartyl-[O-
methyl]- fluoromethylketone, Ventilation: mechanical ventilation with 8 mL/kg tidal volume, f = 180 min-1, one 
RM every 5 min, FiO2 = 0.3 and PEEP = 2 cmH2O. 
 
 
2.7.3 The acid model 
For acid instillation, 0.3% NaCl was titrated with HCl to a pH of either 1.5 or 1.8. 0.3% NaCl 
was used to gain a higher osmolarity, which is better comparable to the osmolarity of the 
gastric content than water. Mice were anaesthetised and tracheotomised as described 
above. After tracheotomy, mice were brought in an upright position. For the intratracheal (i.t.) 
instillation of acid, a commercially available device, the microspayer, was used. The 
microsprayer is a high pressure syringe connected to a very thin cannula that is suitable for 
intubation of mice. For technical reasons mice were not intubated, but the cannula of the 
microsprayer was inserted through the tracheal cannula and was positioned about 3 mm 
above the bronchial bifurcation instead. The microsprayer is constructed to produce an 
aerosol, when the piston is lowered very quickly. In this study, application of acid as an 
aerosol did not induce lung injury. Therefore the acid was applied by lowering the piston 
slowly, whereby a continuous thin stream was ejected by the microsprayer. In this way a 
volume of 50 µL acid [2.5 mL/kg] were injected into the lungs. Control mice received the 
same volume of 0.9% NaCl. After instillation, the microsprayer was removed and the mouse 
was placed upright in one hand of the operator. Then the mouse was carefully shaken up 
and down five times to force the acid into the lungs. The mouse was connected to the 
ventilator immediately and two long RM (P = 30 cmH2O, duration: 6 s) were performed 
before onset of ventilation. Ventilation was performed with VT = 16mL/kg, f = 90 min-1, one 
RM every 5 min, PEEP = 2 cmH2O and FiO2 = 0.3. No additional CO2 was administered in 
this model, because acid-treated mice showed increased pCO2 levels due to impaired gas 
exchange. Control mice, treated with NaCl, were ventilated with additional dead space, 
increased by 3.5 cm, to avoid hypocapnia. Experimental groups are shown in Table 2.3. Two 
independent series of experiments were performed under differential conditions: firstly, the 
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severe acid model with acid pH = 1.5 over 5 h of ventilation and secondly the moderate acid 
model with acid pH = 1.8 over a period of 5 h 30 min ventilation. Therapeutical interventions 
were single dosages of either the glucocorticoid dexamethasone [1mg/kg] or the alkaloid 
quinine [20mg/kg], each given iv in 100 µL of Ringer’s buffer directly after onset of ventilation. 
Control groups received the same volume of Ringer’s buffer without drug. 
 
Table 2.3: Experimental groups in the acid model 
 Severe acid model pH = 1.5 
Moderate acid model 
pH = 1.8 
 SA SAD NaCl5h MA MAD MAQ NaCl5.5h 
Instillation i.t. Acid Acid NaCl Acid Acid Acid NaCl 
Ringer’s i.v. + - + + - - + 
Dexa i.v. - + - - + - - 
Quinine i.v. - - - - - + - 
FiO2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
Ventilation 5 h 5 h 5 h 5.5 h 5.5 h 5.5 h 5.5h 
 
SA: severe acid (pH 1.5), MA: moderate acid (pH 1.8); Instillation i.t.: 50 µL hydrochloric acid or 0.9 % NaCl 
administered intratracheally; Ringer’s i.v.: 100 µL Ringer’s buffer injected into tail vein; Dexa i.v.: 1 mg/kg 
dexamethasone injected intravenously; Quinine iv: 20 mg/kg intravenously; FiO2: fraction of inspired oxygen; 
Ventilation: VT = 16 mL/kg, f = 90 min-1, PEEP = 2 cmH2O and one recruitment manoeuvre every 5 min. 
 
 
2.8 Mouse lung preparation 
2.8.1 Preparation in the ventilation and TNF model 
After thoracotomy, lungs were perfused free of blood. Therefore the left ventricle was opened 
with a cut and the needle of a 27 gauge venous catheter, which was connected to a burette 
filled with ice-cold PBS, was inserted into the pulmonary vein above the right atrium. The 
burette, which was fixed to a stand, was filled to a level of 20 cm height, so that all lungs 
were perfused with a pressure of 20 cmH2O until the tissue became almost white. Then 
thymus and heart were removed, before the lungs were resected carefully from the thorax 
and transferred to a culture dish for further preparation. Next, the left lung was transiently 
disconnected by positioning a micro clamp on the left main bronchus. The right lung was 
then subjected to bronchoalveolar lavage (BAL), by instilling two times 300 µL ice-cold NaCl 
with a syringe via the tracheal tubing. About 550 µL BAL fluid was retrieved from each 
mouse. Following lavage, the right lung was separated by a ligature, cut off and snap frozen 
in liquid nitrogen for storage at -80°C. Thereafter, the micro clamp was carefully taken off the 
left bronchus and the left lung was filled with 4% buffered formalin using a hydrostatic 
pressure of 20 cmH2O to facilitate adequate filling of the alveoli without damaging the tissue. 
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The filled left lung was closed with a ligature and placed in a Falcon tube containing 4% 
formalin for fixation. After fixation for three days at room temperature, lungs were embedded 
in paraffin for histopathological processing. Finally, the BAL fluid was centrifuged for 10 min 
at 3500 rpm. The cell pellet was transferred to a cytospin preparation (2.9.1). The 
supernatant was snap frozen for later quantification of total protein, cytokine and BSA levels 
as described in chapter 2.10.1 and 2.10.2. 
 
2.8.2 Preparation in the acid model 
Perfusion and resection of the whole lung were performed as described in the chapter above 
(2.8.1). Then the right lung was occluded with a micro clamp on the right bronchus, before 
the left lung was lavaged by instilling two times 200 µL ice-cold NaCl, whereof about 350µL 
were retrieved from each mouse. BAL samples were treated as in the other models. After 
ligature of the left bronchus, the left lung was removed. Continuing with the right lung, the 
upper right lobe was separated from the lower lobes by a ligature. The lower lobes were 
removed and immediately frozen in liquid nitrogen. The upper lobe was filled with 4% 
formalin and prepared for histopathology as described above. 
 
 
2.9 Cytospin and Histopathology 
2.9.1 Cytospin preparation 
For the cytospin preparation, a microscopic slide was placed in a metal holder and covered 
with a filter containing two circular holes. Then an acryl glass container with two holes was 
placed on top of the filter so that the holes of the container were positioned above the holes 
of the filter and the filter was tightly fixed on the slide. The cell pellets retrieved from the 
centrifuged BAL fluid samples were resuspended in 150 µL RPMI medium. Each cell 
suspension was pipetted into a 1 mL pipette tip, before the filled tip was inserted into one of 
the holes of the container. The whole construction was placed in a centrifuge and centrifuged 
for 5 min at 300 rpm to enable the cells, which were held back in the tip by capillary forces, to 
be attached to the slide by centrifugal force. The cells on the slide were dried by room air 
followed by a modified Giemsa stain (Diff-Quick). Slides were mounted for preservation until 
evaluation by differential leukocyte count at 200x magnification. 
 
2.9.2 Preparation of tissue slices from paraffin embedded mouse lungs 
Tissue slices were cut with a microtome. Mouse lungs embedded in paraffin blocks were 
placed in the microtome and slices of 1 µm thickness were prepared. The slices were 
transferred into a water bath with lukewarm water and were then mounted on Poly-L-Lysin 
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(0.1%) coated microscope slides. The specimens were dried over night at 37°C before 
further processing. 
 
2.9.3 Haematoxylin-Eosin (HE) staining 
The HE staining of the lung slices was performed by first incubating the slides for 10 min in 
Mayer’s-Haemalaun solution for a blue staining of the cell nuclei. After rinsing the slides with 
water, they were incubated for 10 min in tap water to blue the stain. For the counter stain of 
the cytoplasm the slides were incubated for 5 min in a 1% solution of the acidic red Eosin. 
Slides were again rinsed with water and then dehydrated by shortly dipping them in 70%, 
96% and twice in 100% alcohol. Finally, slides were transferred to xylene and then mounted 
with mounting media and cover slips. 
 
2.9.4 Histopathological scoring 
The lung injury scoring system recently published in the official ATS workshop report on 
features and measurements of experimental lung injury was adopted [34] is briefly 
summarised in Table 2.4 depicted below. The score ranges from 0 to 1. A score of 0 
indicates that no injury occurred, whereas 1 is the maximal injury. 
 
Table 2.4: Histopathological scoring system  
 Score per field 
Parameter 0 1 2 
A. Neutrophils in the alveolar space none 1-5 > 5 
B. Neutrophils in the interstitial space none 1-5 > 5 
C. Hyaline membranes none 1 > 1 
D. Proteinaceous debris filling in the airspaces none 1 > 1 
E. Alveolar septal thickening < 2x 2x-4x > 4x 
 
From each mouse lung, 10 pictures from different regions were taken at 200-fold magnification. The injury score 
was calculated by: Score = [(20 x A) + (14 x B) + (7 x C) + (7 x D) + (2 x E)] / (number of fields x 100). 
 
 
2.10 Biochemical methods 
2.10.1 Protein quantification 
Total protein levels of the BAL fluid were measured using the DC protein assay from Bio-
Rad. This method is based on the Lowry protein assay, which consists of two steps. The first 
step is the Biuret reaction, during which peptide bonds form violet complexes with Cu2+-ions 
in alkaline solution. In the second step, Cu2+ is reduced to Cu+, which then reduces the Folin-
Ciocalteau reagent, inducing a further colour reaction and thereby increasing the sensitivity 
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of the assay. The DC assay returns stable results after 15 min of incubation. Absorbance 
was read at 550 nm. Protein concentrations were determined using a BSA standard curve. 
 
2.10.2 Enzyme-linked immunosorbent assays 
The following mediators were quantified using commercially available enzyme-linked 
immunosorbent assays (ELISA): the pro-inflammatory cytokines interleukin-6 (IL-6) and TNF, 
the chemokines keratinocyte-derived chemokine (KC) and macrophage inflammatory protein-
2 (MIP-2) and the sepsis marker procalcitonin (PCT). Also BSA and HSA were detected with 
ELISA. Due to the limited sample volume from mice, all proteins listed above, except of PCT, 
were measured in diluted samples. BAL samples were diluted 1:4 and plasma samples 1:10. 
The assays were performed according to the manufacturer’s protocols. All kits are listed in 
chapter 2.2.3. 
 
2.10.3 Cell death detection assay 
The cell death detection assay allowed quantification of apoptosis and necrosis via detection 
of mono- and oligonuceosomes by sandwich ELISA. For the assay, 30 mg of homogenized 
frozen lung tissue were lysed with a buffer included in the kit. The assay was performed 
according to the manufacturer’s instructions and absorbance was read at 405 nm. The lysis 
buffer was measured as blank, which was subtracted from the results. Cell death was 
calculated as % per mg lung tissue relative to a 100% positive control. 
 
2.10.4 Nitric oxide quantification assay 
The gaseous signalling molecule nitric oxide (NO) is highly instable in vivo and is rapidly 
converted into the more stable metabolites nitrite (NO2-) and nitrate (NO3-). In the present 
study, an assay was used that measures total NO in blood plasma samples. Therefore, 
endogenous nitrate was converted to nitrite by nitrate reductase. Then the total nitrite was 
quantified as a chromophoric azo-derivative of the Griess reagent by reading the absorbance 
at 550 nm. 
 
2.10.5 Acid sphingomyelinase activity assay 
ASM activity was determined by using 14C-labelled sphingomyelin. For all samples, 10 μg 
protein diluted to 10 μL was incubated at 37°C for 2 h with 40 μL substrate (73 nmol 14C-
labelled sphingomyelin + 400 nmol sphingomyelin). Lipids were separated by chloroform / 
methanol extraction. 4 mL scintillation liquid was added and radioactivity was counted in a β-
counter. 
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2.11 Statistical analysis 
Statistical analyses of time courses, i.e. lung mechanics, BP and HF, were analysed with the 
mixed model procedure followed by correction for false discovery rate (FDR) in the 
ventilation and acid model. To evaluate lung mechanics from the groups lowVTRM60 and 
PEEP6_RM60 in a linear model, one time point every 60 minutes before and one after RM 
were analysed separately, resulting in two separate linear slopes (lowVTRM60a and 
PEEP6_RM60a: before RM, lowVTRM60b and PEEP6_RM60b: after RM). In the TNF model, 
lung mechanics, HF and BP were analysed using Two-Way Analysis of Variance to analyse 
the influence of genotype and drug-treatment as independent factors. Analyses of all other 
parametric data were carried out with One-Way Analysis of Variance, followed by t-test and 
FDR correction or the Tukey-test. BoxCox transformation was performed to achieve 
homoscedasticity, when suitable. Percentage data were transformed using the arcsine 
transformation. The Bartlett test was used to check for equal variances. Normal distribution 
was validated with the Shapiro-Wilk test. Non-parametric data, except of survival curves, 
were analysed with the Kruskall-Wallis test followed by Dunn’s post-test. Survival curves 
were compared with the Kaplan-Meier estimator. Correlation was evaluated with Pearson’s 
correlation coefficient. Cluster analysis was performed with JMP 9 using the method 
‘average’ with standardised data. Data in figures are shown as mean + standard error of the 
mean (SEM). P-values ≤ 0.05 were considered as significant. Statistical analyses were 
carried out with GraphPad Prism 5.0, JMP 7, JMP 9 or SAS 9.1 software.
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3 Results 
 
3.1 The ventilation model with low PEEP (2 cmH2O) 
3.1.1 Lung mechanics 
The first series of ventilation experiments was performed at a PEEP = 2 cmH2O. This low 
PEEP level is commonly used in animal studies that aim to study VILI and is regarded as 
minimally protective (see Table 1.2). Ventilation with 8 mL/kg and no RM (lowVTnoRM) 
caused a continuous decrease of pulmonary compliance (C) over more than two hours that 
reached a plateau at approximately 30% of the physiological baseline value (Fig. 3.1). Within 
this time pulmonary resistance (R) nearly tripled. Resistance and compliance showed less 
dramatic trends in mice ventilated with 16 mL/kg and no RM (highVTnoRM). In this group C 
plateaued earlier (60 min) at about 60% of the baseline value and R increased to a lesser 
degree (~25%). R and C differed significantly between the lowVTnoRM and the highVTnoRM 
group (R: p < 0.01; C: p < 0.001). Respiratory input impedance revealed major alterations in 
the periphery of the lung. Tissue damping (G) and tissue elastance (H) were elevated in both 
highVTnoRM and lowVTnoRM mice, reaching significantly higher values in the lowVTnoRM 
group (G: p < 0.01; H: p < 0.001). In the latter group, airway resistance (Raw) was increased 
as well. The increase in G, H and Raw indicates that low VT ventilation without RM leads to 
closure of peripheral areas of the lung and causes a small degree of airway constriction. In 
consequence, hysteresivity (G/H = η) decreased slightly over time, but was in a comparable 
range in all groups. 
 
These findings indicate that ventilation without RM leads to impaired lung functions, which 
stabilise within two hours, though at a low level. Therefore the effect of repetitive RM 
(30 cmH2O) every 5 min was examined. In both the lowVTRM5 and the highVTRM5 group, 
lung mechanics stayed in a physiological range and remained unchanged during the whole 
experiment. Depending on the different VT, C and H differed reciprocally between low- and 
highVT groups (p < 0.05). The stability of the lung mechanics demonstrates that application of 
deep inflations of 1 s duration and 30 cmH2O are sufficient to prevent the deterioration of 
lung functions in healthy mouse lungs ventilated with 2 cmH2O PEEP and moderate VT. 
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Fig. 3.1: Lung mechanics with PEEP = 2 cmH2O. Mice were ventilated for six hours with low VT = 8 mL/kg or 
high VT = 16 mL/kg, PEEP = 2 cmH2O and RM every five minutes (RM5), every 60 minutes (RM60) or without RM 
(noRM). Lung mechanics were measured every ten minutes by the forced oscillation technique. (LowVTRM5: n=6, 
highVTRM5: n=6, lowVTnoRM: n=5, highVTnoRM: n=4, lowVTRM60: n=5). P-value ranges for group comparisons 
are shown in Table 6.1 in the supplement. 
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Further, it was examined whether it would suffice to apply RM only every 60 min instead of 
every 5 min. This was studied in the low VT group (lowVTRM60) only. In this group, 
respiratory conditions were instable. R and C worsened comparable to the lowVTnoRM 
group, but improved significantly after each RM. These alterations were reflected in changes 
in G and H. However, even though each RM was beneficial, after six hours tissue elastance 
had increased permanently, indicating that one deep inflation per hour is not sufficient to 
maintain lung volume at baseline values. This is illustrated by the finding that H (p < 0.001), 
R, C, G (all p < 0.01) and Raw (p < 0.05) were significantly different between the lowVTRM60 
and the lowVTRM5 group. 
 
3.1.2 Heart frequency, mean arterial pressure and oxygen saturation 
Anaesthesia with pentobarbital sodium resulted in reduced heart frequency (300-400 min-1) 
and mean blood pressure (50-60 mmHg), compared to average data of unsedated mice 
[148]. ECG (data not shown), Heart frequency (HF) and mean arterial pressure (MAP) 
remained unchanged throughout ventilation and were not significantly different between the 
groups (Fig. 3.2). This demonstrates that ventilation and recruitment strategy did not affect 
the circulation. The fluid support with 200 µL NaCl per hour in all groups was adequate to 
keep blood pressure stable. A small peak in HF was caused at the time-point of i.v. BSA 
injection (270 min). Oxygen saturation, measured by pulse oximetry, was over 90% in all 
mice at all times. Oxygen saturation served only as control parameter during the 
experiments, because this parameter is generally prone to interference. For evaluation of gas 
exchange, the more accurate arterial pO2, measured by blood gas analysis, was used. 
 
 
Fig. 3.2: Heart frequency and mean arterial pressure. Electrocardiogram (ECG) was recorded permanently 
beginning with onset of ventilation. A. Heart frequency (HF) was calculated simultaneously from the ECG and is 
displayed in beats per minute (bpm). B. Mean arterial blood pressure (BP) was measured via a catheter in the 
carotid artery. (LowVTRM5 n=6, highVTRM5 n=6, lowVTnoRM n=5, highVTnoRM n=4, lowVTRM60 n=5). 
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3.1.3 Blood gas analysis 
Blood gas analyses revealed that infusion of saline and application of 3% CO2 in the high VT 
groups were adequate to keep the acid-base status stable and that ventilation resulted in 
normocapnia in the lowVTRM5 and highVTRM5 group, with pCO2 levels ranging from 35 to 
40 mmHg (Table 3.1). The pO2/FiO2 ratio was between 530 and 620 mmHg in both RM5 
groups and in the highVTnoRM group (Fig. 3.3A). Most mice ventilated with highVTnoRM had 
physiological pCO2 levels after six hours. The pO2/FiO2 ratio was decreased significantly to 
~200 mmHg in the lowVTnoRM group, indicating acute respiratory failure. In this group, 
impaired gas exchange was further indicated by an increase in pCO2 levels to about 
60 mmHg (Fig. 3.3B), leading to respiratory acidosis with a mean pH of 7.22. Mice in the 
lowVTRM60 group showed very heterogeneous pO2/FiO2 ratios between 260 and 570 mmHg 
and markedly increased pCO2 levels as well as hypercapnic acidosis. HCO3- and standard 
base excess were only slightly reduced and did not indicate metabolic imbalance. 
 
 
Fig. 3.3: Blood gas results with PEEP = 2 cmH2O. Arterial blood was analysed after six hours of ventilation. 
A. The pO2/FiO2 ratio was calculated, FiO2 was 0.5. B. Comparison of pCO2 levels. (LowVTRM5 n=6, highVTRM5 
n=6, lowVTnoRM n=5, highVTnoRM n=4, lowVTRM60 n=5). * p ≤ 0.05, ** p ≤0.01, *** p ≤ 0.001. 
 
Table 3.1: Blood gas results in the ventilation model with PEEP = 2 cmH2O 
 LowVTRM5 HighVTRM5 LowVTnoRM HighVTnoRM LowVTRM60 
pO2 [mmHg] 283.5 ± 13.4 287.7± 12.7  108.6 ± 13.6 261.8 ± 17.8 205.5 ± 72.4 
pCO2 [mmHg] 38.4 ± 3.9 34.9 ± 4.0 58.3 ± 7.61 40.6 ± 15.1 50.1 ± 9.4 
pH 7.33 ± 0.03 7.36 ± 0.04 7.22 ± 0.03 7.32 ± 0.08 7.28 ± 0.05 
HCO3- [mmol/L] 19.5 ± 1.6 19.2 ± 1.6 23.6 ± 2.3 19.7 ± 3.4 21.8 ± 1.9 
SBE [mmol/L] - 6.0 ± 1.6 - 5.5 ± 1.7 - 3.5 ± 2.1 - 5.4 ± 2.3 - 3.5 ± 1.6 
 
Blood gas analyses from arterial blood after 6 h of mechanical ventilation with PEEP = 2 cmH2O. Data are 
shown as mean ± standard deviation. SBE: standard base excess, lowVT: low tidal volume, highVT: high tidal 
volume, RM5: one recruitment manoeuvre every five minutes, noRM: no recruitment manoeuvres, RM60: one 
recruitment manoeuvre every 60 minutes. 
 Results  
  39  
3.1.4 Pulmonary microvascular permeability 
Total protein levels were increased in all ventilated mice, compared to unventilated controls. 
Protein levels were highest in the groups without RM (Fig. 3.4A). The BSA BAL/plasma ratio 
confirmed that ventilation augmented microvascular permeability in the lung, particularly 
when inspiratory pressures were high, as in the groups ventilated without repetitive 
recruitment (Fig. 3.4B). 
 
 
 
Fig. 3.4: Total protein levels and protein leakage with PEEP = 2 cmH2O. A. Total protein levels were 
measured with a Lowry protein quantification assay. (Unventilated n=5, lowVTRM5 n=6, highVTRM5 n=6, 
lowVTnoRM n=4, highVTnoRM n=4, lowVTRM60 n=5). B. BSA was quantified in BAL and serum by ELISA and the 
ratio was calculated. (Unventilated n=5, lowVTRM5 n=5, highVTRM5 n=5, lowVTnoRM n=4, highVTnoRM n=4, 
lowVTRM60 n=5). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
 
3.1.5 Pro-inflammatory mediators 
Interleukin-6 (IL-6) and Keratinocyte-derived chemokine (KC) were elevated in the BAL fluid 
and blood serum from all ventilated mice (Fig. 3.5A, B, E, F). BAL fluid from mice ventilated 
with lowVTRM5 showed a less dramatic increase in these pro-inflammatory cytokines. In both 
RM5 groups serum levels of IL-6 and KC were clearly lower than in all other ventilation 
groups. Interestingly, Interferon-γ induced protein (IP-10) and TNF were not significantly 
increased in the BAL from ventilated mice, compared to unventilated controls (Fig. 3.5C, D). 
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Fig. 3.5: Pro-inflammatory mediators with PEEP = 2 cmH2O. The Cytokines IL-6, IP-10 and TNF as well as 
the chemokine KC were quantified in blood plasma or BAL supernatant with commercial ELISA kits after six hours 
of ventilation and in unventilated mice. (Unventilated n=5, lowVTRM5 n=6, highVTRM5 n=6, lowVTnoRM n=4 in 
BAL and n=5 in serum, highVTnoRM n=4, lowVTRM60 n=5). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, § *** p ≤ 0.001 
versus all other groups. 
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3.1.6 Neutrophil recruitment into the alveolar space 
The only cell types found in BAL fluid of unventilated control mice were monocytes and 
macrophages. In contrast, all samples from ventilated mice also contained neutrophils 
(Fig. 3.6). Numbers of neutrophils were highest in mice ventilated with high VT. Considerably 
less neutrophils were recruited to alveoli of lowVT mice, whereof the group lowVTRM5 had the 
lowest neutrophil count. 
 
 
 
Fig. 3.6: Neutrophils in the BAL fluid with PEEP = 2 cmH2O. BAL fluid was subjected to cytospin preparation, 
followed by modified Giemsa staining. 400 cells were counted from each preparation and the percentage of 
neutrophils was calculated. (Unventilated n=5, lowVTRM5 n=5, highVTRM5 n=5, lowVTnoRM n=4, highVTnoRM 
n=4, lowVTRM60 n=5). * p ≤ 0.05, ** p ≤ 0.01. 
 
 
3.1.7 Lung histopathology 
Examination of HE-stained lung sections showed that only mild lung injury was induced by 
the ventilation strategies applied (Fig. 3.7). This was supported by the employed lung injury 
score, theoretically ranging from zero to maximally one, which was below 0.4 in all subjects. 
Nonetheless, histopathological alterations were present in all ventilated lungs and were most 
pronounced in mice ventilated with high VT (Fig. 3.8). In almost all ventilated lungs, interstitial 
neutrophils were present and in some sections alveolar septae were thickened. In mice 
ventilated with high VT, also intra-alveolar neutrophils were observed. This is in line with the 
results from the differential cell count in the BAL fluid, where highest neutrophil numbers 
were counted in the high VT groups. Neither hyaline membranes nor proteinaceous debris 
were observed in any sections, further demonstrating that the ventilation strategies used in 
this study induced only moderate injury in the healthy lungs. 
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Fig. 3.7: Lung histopathology with PEEP = 2 cmH2O. Representative HE-stained lung sections from: A. 
unventilated control, B. lowVTRM60, C. lowVTRM5, D. highVTRM5, E. lowVTnoRM and F. highVTnoRM mice. 
Black arrows indicate neutrophils; blue arrows indicate intra-alveolar monocytes and macrophages, scale bars 
100 µm; magnification 200x. Insets in A and D contain enlarged images of exemplary leukocytes. 
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Fig. 3.8: Histopathological scoring with PEEP = 2 cmH2O. Lungs were scored with an injury scoring system 
suggested by Matute-Bello et al. [34]. 10 fields per lung were evaluated according to the following criteria: A) 
neutrophils in the alveolar space, B) neutrophils in the interstitial space, C) hyaline membranes, D) proteinaceous 
debris in the airspaces, E) alveolar septal thickening. The score was calculated as follows: Score = [(20 x A) + (14 
x B) + (7 x C) + (7 x D) + (2 x E)] / (number of fields x 100). (Unventilated n=5, lowVTRM5 n=5, highVTRM5 n=5, 
lowVTnoRM n=4, highVTnoRM n=4, lowVTRM60 n=5). * p ≤ 0.05. 
 
 
3.2 The ventilation model with moderate PEEP (6 cmH2O) 
3.2.1 Lung mechanics 
In the second series of experiments the ventilation strategies RM5, noRM and RM60 were 
applied to mice ventilated with low VT and a PEEP of 6 cmH2O, to find out whether the 
impairment of lung mechanics during ventilation with noRM and RM60 could be prevented by 
a higher PEEP (Fig. 3.9). Ventilation with RM5 at a PEEP of 6 cmH2O (PEEP6_RM5) 
showed stable lung functions. Ventilation without RM (PEEP6_noRM) resulted, 
notwithstanding the increased PEEP, in a strong decrease in C during the first 180 min of 
ventilation until a plateau was reached at about 30% of the initial C. Correspondingly R, G 
and H increased and finally doubled in this group. Also ventilation with RM60 
(PEEP6_RM60) did not suffice to keep lung functions entirely stable at a PEEP of 6 cmH2O. 
Although the decrease in C between the RM was relatively moderate, the initial C was not 
maintained over six hours. R, in contrast, returned to the initial value after each RM. In line 
with this, lung impedance measurements revealed a moderate increase in H, but not in G 
after six hours. All three groups differed significantly from each other regarding C, R, H and 
G, except from the parameters measured in the PEEP6_RM60 group directly after the RM. 
Raw and η were not different between the groups and Raw remained at baseline in all 
experiments (data not shown). These results indicate that an elevation of PEEP, although it 
helps to stabilise lung mechanics, is not sufficient to replace repetitive RM. 
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Fig. 3.9: Lung mechanics with PEEP = 6 cmH2O. Mice were ventilated for six hours with low VT = 8 mL/kg, 
PEEP = 6 cmH2O and RM every five minutes (RM5), every 60 minutes (RM60) or without RM (noRM). Lung 
mechanics were measured with the forced oscillation technique every ten minutes. (n = 4 in all groups). Please 
see Table 6.2 in the supplement for p-value ranges of group comparisons. 
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3.2.2 Blood gas analysis 
One aim of the second series of ventilation experiments was to investigate whether a higher 
PEEP can prevent the worsening of gas exchange in mice ventilated at a PEEP = 2 cmH2O 
and RM60 or noRM. The pO2/FiO2 ratio was around 500 mmHg in the PEEP6_RM60 group 
and around 400 mmHg in the PEEP6_noRM group (Fig. 3.10). Both groups differed 
significantly from the control group PEEP6_RM5, which showed unimpaired gas exchange 
with a pO2/FiO2 ratio of about 600 mmHg This further demonstrates that regular RM are 
necessary even with a PEEP of 6 cmH2O. In accordance, pCO2 levels were significantly 
elevated in the groups PEEP6_RM60 and PEEP6_noRM, compared to the control group. 
 
 
 
Fig. 3.10: Blood gas results with PEEP = 6 cmH2O. Arterial blood was analysed after six hours of ventilation. 
A. The pO2/FiO2 ratio was calculated with FiO2 = 0.5. B. Comparison of pCO2 levels (n = 4 in all groups). 
** p ≤ 0.01, *** p ≤ 0.001. 
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3.2.3 Pro-inflammatory mediators 
In the second set of experiments IL-6 and KC levels in the BAL fluid were highest in the 
PEEP6_noRM group, followed by the PEEP6_RM5 group (Fig. 3.11A, B). Both mediators 
were lowest in the PEEP6_noRM group. IL-6 in the blood serum was not significantly 
different between these three groups (Fig. 3.11C). KC levels were highest in the group 
ventilated without RM, but differed only slightly between the groups ventilated with RM5 and 
RM60 (Fig. 3.11D). These results indicate that a higher PEEP helps preventing the release 
of pro-inflammatory mediators induced by formation of atelectasis. 
 
 
 
Fig. 3.11: Pro-inflammatory mediators with PEEP = 6 cmH2O. The cytokine IL-6 and the chemokine KC were 
quantified after 6 h of ventilation in the blood plasma or BAL supernatant by ELISA. (n = 4 in all groups). 
* p ≤ 0.05, ** p ≤ 0.01. 
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3.2.4 Neutrophil quantification in the BAL fluid 
In the second part of the study, in which all mice were ventilated with low VT, neutrophil 
numbers were clearly highest in the group PEEP6_noRM. Neutrophil counts were lower in 
the BAL fluid from PEEP6_RM5 mice and lowest in the PEEP6_RM60 group (Fig. 3.12). 
 
 
 
Fig. 3.12: Neutrophils in the BAL fluid with PEEP = 6 cmH2O. Leukocytes were counted after cytospin 
preparation of the BAL fluid. From each preparation 400 cells were counted and percentage of neutrophils was 
calculated. (n = 4 in all groups). * p ≤ 0.05. 
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3.3 The TNF model 
3.3.1 Lung input impedance 
Systemic application of TNF, 45 min after onset of ventilation, had no relevant influence on 
lung mechanics (Fig. 3.13). 
 
 
 
Fig. 3.13: Lung impedance in TNF-treated mice. Mice were ventilated with VT = 8 mL/kg, f = 180 min-1, 
PEEP = 2 cmH2O and FiO2 = 0.3. All groups, except from the group ASM-/-sham, received 50 µg TNF i.v. 45 min 
after onset of ventilation. In addition, 250µg and 100µg zVad-fmk was given to the groups wt+zVAD and ASM-/-
+zVAD at 30 min and 105 min of ventilation, respectively. (n=5 in all groups). 
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The caspase inhibitor zVAD-fmk had no influence on lung mechanics either. Pulmonary 
resistance and compliance stayed unchanged during the whole period of ventilation and are 
therefore not depicted. Also the more sensitive measurement of lung impedance revealed no 
noteworthy alterations. The central airways were not affected at all, shown by the 
measurement of Raw (Fig. 3.13A). The resistance in the periphery of the lung, given by G, 
was significantly different between TNF-treated and untreated mice (p ≤ 0.01), but the 
difference was within a physiologically unimportant range (Fig. 3.13B). The tissue elastance 
H did not change after TNF treatment (Fig. 3.13C), although it differed basally between wt 
and ASM-/- mice (p ≤ 0.05).  
 
3.3.2 Gas exchange 
Gas exchange was examined by measurement of the arterial pO2 and pCO2 after 405 min of 
ventilation. Two wt mice in each group died prior to exsanguination and could not be 
subjected to blood gas analysis. The Horovitz index was calculated from the pO2 and the 
applied FiO2 of 0.3 to evaluate the level of oxygenation (Fig. 3.14A). The index was between 
500 and 600 mmHg in all subjects, thus being in the range of healthy lungs. The pCO2 levels 
around 40 mmHg were in a normal range as well (Fig. 3.14B). In conclusion, the arterial 
blood gases showed no impairment of pulmonary gas exchange supporting the result of the 
impedance measurement that TNF had no influence on lung functions. 
 
 
 
Fig. 3.14: Gas exchange in TNF-treated mice. Arterial pO2 and pCO2 were measured after 405 min of 
ventilation by blood gas analysis. A. The Horovitz index, calculated with FiO2 = 0.3, was in a normal range in all 
subjects. B. The pCO2 levels showed no impairment of gas exchange. All groups, except from the group ASM-/-
sham, received 50 µg TNF i.v.. In addition, zVad-fmk was injected i.v. to the groups wt+zVAD and ASM-/-+zVAD. 
(wt -zVAD n=3, wt +zVAD n=3, ASM-/- -zVAD n=5, ASM-/- +zVAD n=5, ASM-/- sham n=5). 
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3.3.3 Pro-inflammatory mediators 
Quantification of pro-inflammatory mediators in the BAL fluid and blood serum was 
performed by ELISA. TNF was measured to ascertain how much of the 50 µg that had been 
injected i.v. was present in the circulation and in the lung. Fig. 3.15A shows that at least 
about 1000 ng/mL TNF were detectable in the plasma in all groups. In some mice in the 
group wt-zVAD, TNF plasma levels were higher. Of note, higher plasma TNF levels did not 
correlate with a reduced survival. No TNF was present in the plasma of the group ASM-/-
sham. In the BAL, mean TNF levels ranged from around 600 to 1500 pg/mL in the TNF-
treated groups (Fig. 3.15D). Compared to the ASM-/-sham group, with a mean of 15 pg/mL, 
relatively high amounts of TNF were found in the alveoli of the TNF-treated groups. 
 
 
 
Fig. 3.15: Pro-inflammatory mediators in TNF-treated mice. The cytokines TNF and IL-6 and the chemokine 
MIP-2 were measured in the BAL fluid and blood plasma by ELISA after 405 min of ventilation. All groups, except 
from the group ASM-/-sham, received 50 µg TNF i.v.. In addition, zVad-fmk was injected i.v. to the groups 
wt+zVAD and ASM-/-+zVAD. (wt -zVAD n=4, wt +zVAD n=5, ASM-/- -zVAD n=5, ASM-/- +zVAD n=5, ASM-/- sham 
n=6). * p ≤ 0.05, ** p ≤ 0.01, § *** p ≤ 0.001 versus all other groups. 
 
 Results  
  51  
High concentrations of the chemokine macrophage inflammatory protein-2 (MIP-2) were 
measured in the blood plasma of all groups six hours after TNF-injection, with higher levels in 
the wt than in the ASM-/- groups (Fig. 3.15B). In contrast, in the lungs MIP-2 was in a very 
low range (<300 pg/mL) only (Fig. 3.15E). MIP-2 concentrations were at least ten-fold higher 
in the plasma than in the lavage, indicating that the chemotactic gradient was directed 
towards the vascular side. Compared to the ventilated sham group, MIP-2 was slightly 
increased in the BAL of the groups ASM-/--zVAD and ASM-/-+zVAD. This was also the case 
for the BAL IL-6 levels (Fig. 3.15F). Overall, alveolar IL-6 was in a normal range for ventilated 
mice in all groups and similar to the results shown in the lowVTRM5 mice in the ventilation 
study (Fig. 3.5). In the plasma of the untreated sham group, the mean IL-6 was 1350 pg/mL 
Fig. 3.15C). This is also comparable to data from the first ventilation study. In the groups that 
were injected with TNF, IL-6 was strongly increased (>50 ng/mL). 
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3.3.4 Microvascular permeability 
In the TNF model, permeability was assessed by an indirect and a direct method. The 
quantification of neutrophil numbers in the BAL, shown in Fig. 3.16A, served as indirect 
measure for permeability. Despite of the ventilation, only very few neutrophils had 
sequestered the lungs of wt mice (1-2%). Neutrophil counts were slightly higher in the groups 
ASM-/--zVAD (12%) and ASM-/-+zVAD (6%). This result could be explained by the higher 
MIP-2 levels in these groups (Fig. 3.15D). Interestingly, about 45% of the leukocytes in the 
lungs of the group ASM-/-sham were neutrophils, indicating that the phenotype of the ASM-/- 
mice included alterations in the lungs. The ratio of i.v. injected BSA quantified in the BAL and 
in the plasma was calculated as direct measure for permeability. The albumin ratio, depicted 
in (Fig. 3.16B), was < 1 in most of the TNF-treated mice. According to literature [130], this is 
a normal range for ventilated mice. The albumin data from the TNF model is not comparable 
to the ventilation study in this thesis, because a different BSA detection ELISA had to be 
used. The ASM-/-sham group differed with a mean albumin ratio of 2.7. These results indicate 
that the microvascular permeability was not altered by TNF, but was increased per se in 
ASM-/- mice. Moreover, TNF-treatment seemed to have protected these mice from neutrophil 
recruitment and increased permeability, promoting the idea that the high systemic TNF-levels 
induced formation of a chemotactic gradient that was directed towards the vascular side. 
 
 
 
Fig. 3.16: Microvascular permeability in TNF-treated mice. A. Neutrophils in the BAL after cytospin 
preparation. The percentage of neutrophils from 400 total leukocytes was calculated. B. Albumin influx into the 
lungs shown as ratio of bovine serum albumin (BSA) quantified in the BAL and in the blood plasma. All groups, 
except from the group ASM-/-sham, received 50 µg TNF i.v.. In addition, zVad-fmk was injected i.v. to the groups 
wt+zVAD and ASM-/-+zVAD. (wt -zVAD n=5, wt +zVAD n=4, ASM-/- -zVAD n=4, ASM-/- +zVAD n=5, ASM-/- sham 
n=6). §* p ≤ 0.05 versus all other groups, § *** p ≤ 0.001 versus all other groups. 
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3.3.5 Lung histopathology 
Histopathological examination revealed that the alveoli of ASM-/- mice contained enlarged 
lipid-storing macrophages, so called foamy cells. These cells were found in TNF-treated and 
untreated mice (Fig. 3.17B, C), demonstrating that their appearance was not induced by 
TNF. The lung injury score showed that no severe injury was present in any group, further 
indicating that the high systemic TNF levels did not harm the lungs. The only criterion 
according to the scoring system, found in all lungs, was recruitment of interstitial neutrophils. 
 
 
 
Fig. 3.17: Influence of TNF and ASM on lung histopathology. Representative HE-stained sections from: A. wt-
zVAD, B. ASM-/--zVAD, C. ASM-/-sham. Black arrows indicate neutrophils, blue arrows enlarged macrophages. 
Scale bars: 100 µm; magnification: 200x. D. The injury score was assessed as described in Fig. 3.8. 
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3.3.6 Cell death in the lung 
Cell death is shown in Fig. 3.18 as relative percentage compared to a positive control that 
was assumed as 100%. Independent from TNF-treatment, relative cell death was about twice 
as high in all ASM-deficient groups compared to the wt groups. Of note, also the ASM-/-sham 
mice revealed a higher level of cell death than the TNF-treated wt mice. The caspase-
inhibitor zVAD-fmk showed a small, although not significant, inhibitory effect on relative cell 
death.  
 
 
Fig. 3.18: Relative cell death in the lungs of TNF-treated mice. Cell death, including apoptosis and necrosis, 
was quantified in homogenised lung tissue with an ELISA that detects mono- and olignucleosomes. All groups, 
except from the group ASM-/-sham, received 50 µg TNF i.v.. In addition, zVad-fmk was injected i.v. to the groups 
wt+zVAD and ASM-/-+zVAD. (wt -zVAD n=5, wt +zVAD n=4, ASM-/- -zVAD n=5, ASM-/- +zVAD n=5, ASM-/- sham 
n=6). * p ≤ 0.05, ** p ≤ 0.01. 
 
 
3.3.7 Arterial acid base status 
Measurement of arterial pH and HCO3- revealed that all TNF-treated mice suffered from 
severe metabolic acidosis (Fig. 3.19). Acidosis is defined as an arterial blood pH < 7.3. The 
metabolic origination was further indicated by the fact that these mice were normocapnic, as 
shown above in Fig. 3.14B. One cause of metabolic acidosis is an impairment of the 
microcirculation as given during circulatory shock. The presence of metabolic acidosis after 
TNF-treatment indicates that TNF could have induced septic shock in this model. 
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Fig. 3.19: Arterial pH and bicarbonate values in TNF-treated mice. The acid-base status was examined by 
blood gas analysis at the end of the experiment (405 min). Normal values in healthy mice are: pH = 7.37, 
bicarbonate (HCO3-) = 22 mmol/L. All groups, except from the group ASM-/-sham, received 50 µg TNF i.v.. In 
addition, zVad-fmk was injected i.v. to the groups wt+zVAD and ASM-/-+zVAD. (wt -zVAD n=3, wt +zVAD n=3, 
ASM-/- -zVAD n=5, ASM-/- +zVAD n=5, ASM-/- sham n=5). § *** p ≤ 0.001 versus all other groups. 
 
 
3.3.8 Procalcitonin plasma levels 
The sepsis marker procalcitonin (PCT), measured in the blood plasma six hours after TNF 
injection, was in a range that indicates sepsis (>2000 ng/L) in all TNF-treated animals. No 
PCT was detectable in the control group ASM-/-sham. These data support that the injected 
TNF dosage sufficed to induce sepsis. 
 
 
 
Fig. 3.20: Procalcitonin levels in TNF-treated mice. Procalcitonin (PCT) was quantified in the blood plasma 
with a commercial ELISA kit for mouse PCT. Levels above 2000 ng/L indicate sepsis. All groups, except from the 
group ASM-/-sham, received 50 µg TNF i.v.. In addition, zVad-fmk was injected i.v. to the groups wt+zVAD and 
ASM-/-+zVAD. (wt -zVAD n=4, wt +zVAD n=4, ASM-/- -zVAD n=5, ASM-/- +zVAD n=5, ASM-/- sham n=6). 
** p ≤ 0.01, § *** p ≤ 0.001 versus all other groups. 
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3.3.9 Influence of TNF on the systemic circulation 
TNF-treatment impaired the systemic circulation in wt, but not in ASM-/- mice. Fig. 3.21B 
shows that the MAP decreased strongly over time in both wt groups, reaching critically low 
values about four hours after TNF injection. MAP in ASM-/- mice stayed stable, indicating that 
these mice were protected from the cardiovascular effects. The HF, which was recorded 
independently from the MAP, ascended in all TNF treated groups, with a significantly higher 
increase in the groups wt-zVAD and wt+zVAD. Given the very low MAP in these groups the 
increase in HF can be interpreted as reflex tachycardia. The depression of the systemic 
circulation further supports that TNF induced septic shock. 
 
 
 
Fig. 3.21: Cardiovascular parameters after TNF-treatment. TNF was injected at 45 min to all groups, except 
from the group ASM-/-sham. The groups wt+zVAD and ASM-/-+zVAD additionally received 250µg and 100µg 
zVad-fmk at 30 min and 105 min of ventilation, respectively. A. The heart frequency (HF) was calculated from the 
electrocardiogram that was recorded permanently. B. Mean arterial pressure (MAP) was measured in the carotid 
artery. Due to the preparation time for the arterial catheter, pressure could not be measured from the beginning of 
the experiment. Cardiovascular parameters were analysed with two-way ANOVA. The influence of ASM-
deficiency was highly significant with p ≤ 0.01 for HF and p ≤ 0.001 for MAP. TNF-treatment had a significant 
effect on HF with p ≤ 0.001 (n=5 in all groups). Caspase-inhibition with zVAD-fmk had no significant influence. 
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3.3.10 Survival analysis of TNF-treated mice 
The survival analysis was performed to investigate the influence of ASM-deficiency on the 
survival in TNF-treated mice (Fig. 3.22). None of the ASM-/- mice died during the experiment. 
In contrast, four of the wt mice died within the 405 min of ventilation, whereof two had 
received zVAD-fmk and two had not. The survival curves of the two strains differed 
significantly (p < 0.05), demonstrating that ASM-deficiency had a protective effect on TNF-
induced lethality. 
 
 
 
Fig. 3.22: Survival in TNF-treated mice. Survival was compared by univariate Kaplan-Meier analysis in TNF-
treated wt and ASM-/- mice. The -zVAD and +zVAD treated groups of each strain were pooled, because zVAD-
fmk had no influence on survival, resulting in n = 10 subjects in each group. The control group ASM-/-sham was 
not included. All TNF-treated ASM-/- mice survived, whereas 4 wt mice (2 wt-zVAD and 2 wt+zVAD) died during 
the experiment. Vertical ticks indicate censored cases at 405 min. 
 
 
3.3.11 Nitric oxide levels in the plasma 
Quantification of nitric oxide (NO) levels, a gaseous signalling molecule with vasodilatative 
properties, showed only minor differences within the groups that had been treated with TNF. 
Neither the ASM-deficiency nor the caspase inhibition had a significant influence. Of note, 
only minor concentrations of NO were detected in the group ASM-/-sham, indicating that TNF 
had induced the release of NO, which probably contributed to the development of shock. 
One limitation of this assay is that haemoglobin interferes with NO reduction, leading to 
decreased NO levels in haemolysed plasma samples [149]. Haemolysis can be induced by 
sepsis and was observed in several blood samples. Therefore, it cannot be excluded that 
differences between the groups were masked due to haemolysis. 
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Fig. 3.23: Total nitric oxide (NO) in the plasma of TNF-treated mice. The stable NO metabolites nitrite and 
nitrate were quantified in the blood plasma, which was retrieved at the end of the experiment. All groups, except 
from the group ASM-/-sham, received 50 µg TNF i.v.. In addition, zVad-fmk was injected i.v. to the groups 
wt+zVAD and ASM-/-+zVAD. (wt -zVAD n=4, wt +zVAD n=4, ASM-/- -zVAD n=5, ASM-/- +zVAD n=5, ASM-/- sham 
n=6). § *** p ≤ 0.001 versus all other groups. 
 
 
3.3.12 Acid sphingomyelinase activity in the urine 
The activity of ASM in the urine was measured as indirect proof for the genotypes of the 
examined mice. An activity level < 300 pmol/mg/h was regarded as zero level. Fig. 3.24 
illustrates that no ASM activity was present in the ASM-/- mice in contrast to the wt mice, 
where ASM activity was detected in all subjects. The low activity range in the wt mice was 
possibly due to the freezing and thawing of the samples. 
 
 
Fig. 3.24: ASM activity in the urine of TNF-treated mice. ASM activity was measured with radioactively labelled 
sphingomyelin as substrate. Activity levels ≤ 300 were regarded as zero level. All groups, except from the group 
ASM-/-sham, received 50 µg TNF i.v.. In addition, zVad-fmk was injected i.v. to the groups wt+zVAD and ASM-/-
+zVAD. (wt -zVAD n=5, wt +zVAD n=5, ASM-/- -zVAD n=5, ASM-/- +zVAD n=5, ASM-/- sham n=6). #*** p ≤ 0.001 
versus ASM-/- -zVAD, ASM-/- +zVAD and ASM-/- sham. 
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3.4 The severe acid model 
3.4.1 Lung mechanics 
Measurement of lung mechanics revealed that acid with pH 1.5 had a strong influence on the 
lung (Fig. 3.25). 
 
 
 
Fig. 3.25: Lung mechanics in the severe acid model. Mice were instilled i.t. with either 50 µL of acid pH 1.5 
(SA) or 0.9% NaCl (NaCl5h) and were ventilated for 300 min at VT = 16 mL/kg, f = 90 min-1, PEEP = 2 cmH2O and 
FiO2 = 0.3. One acid-instilled group was medicated with 1 mg/kg dexamethasone (SAD). Lung mechanics were 
measured using the forced oscillation technique. (n = 5 in all groups). Please see Table 6.3 in the supplement for 
p-value ranges of group comparisons.  
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C as well as R worsened permanently over time in the group SA (severe acid), reaching 
critical ranges with a compliance < 0.02 mL/cmH2O and a resistance > 1.0 cmH2Os/mL after 
about two hours. The NaCl-instilled control group (NaCl5h) showed stable lung functions, 
demonstrating that the impairment of lung functions was not due to the amount of fluid that 
had been administered to the lungs. The third group in this study was treated with 1 mg/kg of 
the glucocorticoid dexamethasone (SAD) i.v.. Interestingly, this treatment had no influence 
on lung mechanics. The lung impedance measurement clarified that acid-instillation had 
strongly affected H and G, without influencing Raw. H and G almost doubled during five hours 
in both acid-instilled groups SA and SAD and differed significantly from the group NaCl5h 
(p ≤ 0.001). Notably, this was not reflected in a change in hysteresivity, which stayed almost 
unchanged in all three groups. 
 
3.4.2 Cardiovascular parameters 
HF and MAP were relatively stable in the acid and NaCl treated groups as shown in 
Fig. 3.26. The slight peak in both parameters at 230 min was due to the i.v. injection of HSA. 
Dexamethasone caused a small increase in MAP, which was accompanied by a higher urine 
production in the group SAD. However, the difference in MAP was not significant. 
 
 
 
Fig. 3.26: Cardiovascular parameters in the severe acid model. A. Heart frequency (HF) and B. Mean arterial 
pressure (MAP) were recorded as described above (Fig. 3.21). NaCl5h: NaCl-instilled control group, SA: acid-
instilled group, SAD: acid-instilled group treated with dexamethasone. (n = 5 in all groups). 
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3.4.3 Oxygenation 
The Horovitz index was between 400 and 500 mmHg in the NaCl5h control group (Fig. 3.27). 
According to the blood gas results in the ventilation study, the oxygenation index ranged 
between 500 and 600 mmHg in untreated lungs ventilated with 16 mL/kg. This indicates that 
application of 50 µL fluid caused a small impairment in gas exchange in the acid model. In 
both acid-instilled groups SA and SAD, oxygenation was strongly decreased to around 
200 mmHg, demonstrating that the gas exchange in the lung was strongly impaired after 
application of acid with pH 1.5. Dexamethasone failed to improve oxygenation.  
 
 
 
Fig. 3.27: Oxygenation in the severe acid model. The Horovitz index was calculated with the arterial p02 
measured after 300 min of ventilation with FiO2 = 0.3. NaCl5h: NaCl-instilled control group, SA: acid-instilled 
group, SAD: acid-instilled group treated with dexamethasone. (n = 5 in all groups). § *** p ≤ 0.001 versus all other 
groups. 
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3.4.4 Pro-inflammatory mediators 
The cytokine IL-6 was strongly increased in the BAL fluid of the acid-treated SA mice, 
compared to the NaCl5h group (Fig. 3.28A). Plasma IL-6 levels were elevated as well, but to 
a lesser degree (Fig. 3.28D). In the BAL of the dexamethasone-treated group SAD, IL-6 was 
significantly lower than in the group SA, reaching the niveau of the control group NaCl5h. In 
the plasma of the group SAD, the IL-6 concentration was even lower than in the NaCl-treated 
control group. Acid-instillation caused also a clear increase of the chemokine KC in the BAL 
and in the plasma (Fig. 3.28B, E). This was not the case after dexamethasone injection. The 
susceptibility of the IL-6 and KC levels to dexamethasone treatment shows that the 
glucocorticoid had an anti-inflammatory effect and was actually effective. Interestingly, also 
TNF was markedly elevated in the BAL fluid after acid instillation (Fig. 3.28C). TNF levels 
were lower in the group SAD than in the group SA, though the difference was not significant. 
 
 
 
Fig. 3.28: Pro-inflammatory mediators in the severe acid model. The cytokines IL-6 and TNF and the 
chemokine KC were measured in the BAL fluid and blood plasma with ELISA after 300 min of ventilation. TNF 
was below the detection limit in the blood plasma. NaCl5h: NaCl-instilled control group, SA: acid-instilled group, 
SAD: acid-instilled group treated with dexamethasone. (n = 5 in all groups). *** p ≤ 0.001; § ** p ≤ 0.01, § 
*** p ≤ 0.001 versus all other groups. 
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3.4.5 Microvascular permeability 
Microvascular permeability was strongly affected in the severe acid model. Neutrophil 
numbers were clearly increased in the acid-treated mice compared to the NaCl controls 
(Fig. 3.29). Correspondingly, also the albumin influx was at a very high level after acid-
treatment. Dexamethasone significantly decreased these effects revealing a protective 
function on the acid-challenged alveolar-capillary barrier. 
 
 
 
Fig. 3.29: Neutrophil counts and albumin influx in the severe acid model. A. Neutrophils were quantified in 
the BAL fluid after cytospin preparation and differential staining as described above Fig. 3.16. B. Albumin influx 
into the lungs shown as ratio of human serum albumin (HSA) quantified in the BAL and in the blood plasma. 
NaCl5h: NaCl-instilled control group, SA: acid-instilled group, SAD: acid-instilled group treated with 
dexamethasone. (n = 5 in all groups). ** p ≤ 0.01, *** p ≤ 0.001, § * p ≤ 0.05 versus all other groups. 
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3.4.6 Lung histopathology 
Acid-induced lung injury was characterised mainly by accumulation of intra-alveolar and 
interstitial neutrophils. Moderate thickening of alveolar septae was only observed in some 
regions of the acid-treated lungs (Fig. 3.30A). Although dexamethasone failed to prevent 
physiological dysfunction, the lung injury score was significantly lower in the steroid-treated 
group (Fig. 3.30B, D). NaCl-instillation had no effect distinct from ventilation-induced 
alterations (Fig. 3.30C), which were alveolar septal thickening and neutrophil infiltration.  
 
 
 
Fig. 3.30: Lung histopathology in the severe acid model. Representative HE-stained sections from: A. Acid 
instilled mouse (SA), B. Acid-instilled, dexamethasone-treated mouse (SAD), C. NaCl-instilled mouse (NaCl5h). 
D. Lung injury score, determined as described above Fig. 3.8. Blue arrows indicate neutrophils, scale bars: 
100 µm; magnification: 200x. (NaCl5h n=5, SA n=4, SAD n=5). ** p ≤ 0.01. 
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3.5 The moderate acid model 
3.5.1 Establishment of the moderate acid model 
The strongly impaired lung functions and resulting hypoxemia, which were not susceptible to 
steroid therapy, indicated that the injury induced within 300 min with an acid of pH 1.5 was 
extremely severe. Therefore, the next approach was to establish an attenuated acid model. 
The only feasible method to achieve this was increasing the pH of the acid. As it is known 
from literature, acid-induced lung injury is pH-dependent and does not occur with a pH > 2.5 
[63]. In consequence, the pH was increased only slightly to pH 1.8 in this thesis. As a result, 
the oxygenation was no longer significantly different from the NaCl-instilled control mice after 
300 min of ventilation (data not shown). Since lung functions worsened continuously over 
time, the next step was to find the right point of time to terminate the experiment after onset 
of hypoxemia. The fact that blood gas measurements could not be performed during the 
experiments led to the question, what else could indicate whether hypoxemia was present. 
Analysis of data from 50 acid- or NaCl-instilled mice in this study revealed that the pulmonary 
compliance and the Horovitz ratio correlated well with each other (p < 0.0001) (Fig. 3.31). A 
compliance < 0.02 mL/cmH2O was associated with an oxygenation index ≤ 300 mmHg, 
indicating lung injury. In consequence, mice were instilled with acid pH 1.8 and ventilated 
until the compliance was < 0.02 mL/cmH2O. In preliminary experiments this was the case 
after 330 min. Thus, the second acid study was performed with acid pH 1.8 and a duration of 
330 min. 
 
 
 
Fig. 3.31: Correlation of pulmonary compliance (C) with the Horovitz index (pO2/FiO2). Data were retrieved 
from mice (n = 50), which were instilled either with 50 µL of acid or 0.9% NaCl and were then ventilated for 5-6 h. 
The grey box indicates that a compliance < 0.02 mL/cmH2O was associated with hypoxemia (pO2/FiO2 
≤ 300 mmHg). R2: goodness of fit, Pearson’s r = 0.91. 
 
Results 
66 
3.5.2 Lung mechanics 
Instillation of acid with pH 1.8 resulted in impaired lung mechanics, although to a lesser 
extent than acid with pH 1.5, as depicted in Fig. 3.32. 
 
 
 
Fig. 3.32: Lung mechanics in the moderate acid model. Mice received 50 µl of 0.9% NaCl (NaCl5.5h) or acid at 
pH 1.8 i.t. (MA) and were ventilated for 330 min at VT = 16 mL/kg, f = 90 min-1, PEEP = 2 cmH2O and FiO2 = 0.3. 
One group of acid-instilled mice was treated with 1 mg/kg dexamethasone (MAD) and one with 20 mg/kg Quinine 
(MAQ). Lung mechanics were assessed with the forced oscillation technique. (NaCl5.5h n=5, MA n=6, MAD n=5, 
MAQ n=6). Please see Table 6.4 in the supplement for p-value ranges of group comparisons. 
 Results  
  67  
In the acid-treated group MA, C was reduced to around 0.02 mL/cmH2O after 330 min, so 
that experiments were terminated at this time point under the assumption that this 
compliance level correlated with a Horovitz index ≤ 300 mmHg. R increased continuously, 
but stayed below 1 cmH2Os/mL. Impedance measurement showed that H increased by 
about 50% of the initial value, which is only half as much as in the severe model. Of note, the 
effect on G was only very small in this model. Further, hysteresivity and Raw changed only in 
physiologically unimportant ranges. Interestingly, the treatment with dexamethasone 
successfully prevented the acid-induced alterations of lung mechanics. Although a very slight 
steady loss of C was recorded, all other parameters were comparable to the results in the 
NaCl5.5h group, which served as control and showed very stable lung functions. R, C, G and 
H in the NaCl5.5h and MAD group were significantly different from the group MA (p < 0.01). 
After the successful treatment with the glucocorticoid, a second therapeutical approach was 
tested using quinine. However this approach did not improve the loss of function due to acid-
instillation. R as well as the tissue properties C, G and H were impaired in the group MAQ to 
the same degree as in the group MA. 
 
3.5.3 Cardiovascular parameters 
As already demonstrated in the severe acid model, HF and MAP were largely unaffected by 
acid-instillation (Fig. 3.33). HSA-injection at 240 min caused a small peak in HF and BP in 
some mice. Interestingly, dexamethasone increased the MAP significantly compared to the 
control group and the group MA, although this had no clear consequence for the HF. 
 
 
 
Fig. 3.33: Cardiovascular parameters in the moderate acid model. A. Heart frequency (HF) and B. mean 
arterial pressure (MAP) were recorded as described above (Fig. 3.21). NaCl5.5h: NaCl-instilled control group, MA: 
acid-instilled group, MAD: acid-instilled group treated with dexamethasone, MAQ: acid-instilled group treated with 
quinine. Mixed model analysis revealed that the group MAD had a significantly increased MAP compared to the 
groups NaCl5.5h (p ≤ 0.001) and MA (p ≤ 0.05). (NaCl5.5h n=5, MA n=6, MAD n=5, MAQ n=6). 
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3.5.4 Oxygenation 
The Horovitz index was around 300 mmHg in the acid-treated group MA after 330 min of 
ventilation, indicating that the approach of correlating compliance with oxygenation to 
evaluate onset of lung injury, had been successful (Fig. 3.34). Oxygenation was around 
500 mmHg in the control group NaCl5.5h and thereby almost comparable to uninstilled lungs. 
The glucocorticoid therapy successfully improved oxygenation, which was in a comparable 
range in the group MAD and in the control group, whereas quinine was not effective. 
 
 
 
Fig. 3.34: Oxygenation in the moderate acid model. The Horovitz index was calculated with the arterial pO2 
measured after 330min of ventilation by blood gas analysis and FiO2 = 0.3. NaCl5.5h: NaCl-instilled control group, 
MA: acid-instilled group, MAD: acid-instilled group treated with dexamethasone, MAQ: acid-instilled group treated 
with quinine. (NaCl5.5h n=5, MA n=6, MAD n=5, MAQ n=6). ** p ≤ 0.01, *** p ≤ 0.001. 
 
 
3.5.5 Pro-inflammatory mediators 
The mediators IL-6, TNF and KC clearly responded to the acid challenge of the lungs, as 
indicated by the significant increase between the control group NaCl5.5h and the group MA 
(Fig. 3.35). This response was weaker than with acid pH 1.5 (Fig. 3.28), reflecting that the 
injury was attenuated with acid pH 1.8. TNF was again below the detection limit in the blood 
plasma of all groups. IL-6 and KC were increased in the acid-instilled group MA. IL-6 was in 
the same range as in the severe model, but the concentration of the chemokine KC was 
lower than before, showing that the systemic response to acid pH 1.8 was mitigated as well. 
The liberation of all three mediators in the lung was strongly reduced by dexamethasone to a 
level that was comparable to the control group. This effect was also observed in the plasma, 
where KC and IL-6 were decreased even below the concentrations detected in the NaCl5.5h 
group. Of note, quinine was not only ineffective in preventing the impairment of lung 
mechanics and oxygenation, but also in anticipating the inflammatory response. In the group 
MAQ, BAL and plasma levels of the quantified mediators were similar as in the group MA. 
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Fig. 3.35: Pro-inflammatory mediators in the moderate acid model. The cytokines IL-6 and TNF as well as 
the chemokine KC were quantified in the BAL fluid and blood plasma by ELISA after 330 min of ventilation. TNF 
was below the detection limit in the plasma. NaCl5.5h: NaCl-instilled control group, MA: acid-instilled group, MAD: 
acid-instilled group treated with dexamethasone, MAQ: acid-instilled group treated with quinine. (NaCl5.5h n=5, MA 
n=6, MAD n=5, MAQ n=6). * p ≤ 0.05,** p ≤ 0.01, *** p ≤ 0.001. 
 
 
3.5.6 Microvascular permeability 
No significant differences were observed concerning the number of neutrophils in the BAL 
between the groups in the moderate acid model (Fig. 3.36A). The small difference between 
the groups, MA, MAQ and NaCl5.5h is probably due to the moderate effect of acid with pH 1.8. 
In the group NaCl5.5h the number of intra-alveolar neutrophils was slightly higher in 
comparison to the control group NaCl5h in the severe model, which might be due to the 
longer period of ventilation. Nevertheless, the group MAD indicated clearly that 
dexamethasone had an inhibitory influence on neutrophil recruitment. The situation is much 
clearer regarding albumin influx (Fig. 3.36B). Acid with pH 1.8 strongly increased albumin 
leakage from a level between 1 and 2 in the control group, which can be regarded as normal 
for ventilated mice, to a mean index of around 8. Dexamethasone prevented albumin 
leakage successfully, whereas quinine revealed no protective effect. 
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Fig. 3.36: Microvascular permeability in the moderate acid model. A. Neutrophil counts determined in the 
BAL as explained in Fig. 3.16. B. HSA was quantified in the BAL and plasma by ELISA to assess albumin 
leakage. NaCl5.5h: NaCl-instilled group, MA: acid-instilled group, MAD: acid-instilled group treated with 
dexamethasone, MAQ: acid-instilled group treated with quinine. (NaCl5.5h n=5, MA n=6, MAD n=5, MAQ n=6). 
** p ≤ 0.01, *** p ≤ 0.001. 
 
 
3.5.7 Lung injury score 
The lung injury score revealed that instillation of acid pH 1.8 induced only small 
histopathological changes, which did not result in significant differences between the groups 
(Fig. 3.37). The group MA received a slightly higher score than the group NaCl5.5h, due to a 
higher number of neutrophils in the alveoli and the interstitial space. As also demonstrated by 
the cytospin preparation (Fig. 3.36A), the steroid-treated group MAD was protected from 
neutrophil sequestration, resulting in a slightly lower score than in the group MA. Finally, the 
score of the quinine-treated group MAQ was in the same range as the group MA, indicating 
that quinine had no protective effect. 
 
 
 
Fig. 3.37: Lung injury score in the moderate acid model. The injury score was determined as described above 
Fig. 3.8. NaCl5.5h: NaCl-instilled group, MA: acid-instilled group, MAD: acid-instilled group treated with 
dexamethasone, MAQ: acid-instilled group treated with quinine. (NaCl5.5h n=3, MA n=5, MAD n=4, MAQ n=6). 
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3.6 Concluding cluster analysis 
Finally, a cluster analysis was performed, in which the groups from the ventilation study at 
PEEP = 2 cmH2O, the TNF study and both acid studies were included. The ventilation model 
at PEEP = 6 cmH2O was excluded, because albumin leakage had not been assessed in this 
study and further because this series of experiments covered the same aspects of injury as 
the ventilation study at PEEP = 2 cmH2O. A control group with idealised values for healthy 
mice was added, because oxygenation and elastance could not be assessed in unventilated 
control mice in the present setup. This analysis aimed to discover common features in the 
different injury models. The following criteria were analysed: albumin leakage as indicator of 
oedema, neutrophil recruitment as hallmark of pulmonary inflammation, hypoxemia and 
pulmonary elastance (H) as indicators of physiological dysfunction. To be able to compare 
albumin leakage, which had been assessed by different ELISA kits in the single studies, the 
leakage was categorised from low to high. Hypoxemia reflects the difference between an 
ideal oxygenation (600 mmHg) and the measured Horovitz index. The hierarchical clustering, 
which is depicted in Fig. 3.38, revealed four clusters: cluster I (green labelling) comprised all 
groups, in which the injury parameters were at a low levels, indicated by the green coloured 
fields. The colourless to pink fields indicate moderate alterations, which were also present in 
some groups in this cluster. Cluster II (red labelling) included the groups lowVTnoRM, 
lowVTRM60 and SAD. The red fields reflect a strong increase in hypoxemia and H in this 
cluster, whereas oedema and inflammation played only a minor role. This is not the case in 
cluster III (blue labelling), which consists of the groups MA and MAQ. Herein all four 
parameters were changed to a moderate degree. Cluster IV (black labelling) contains only 
the group SA, in which all criteria were increased severely. This cluster stands out from the 
other three clusters, which is also indicated by the very long distance to the other clusters in 
the dendogram. For each cluster a parallel plot is shown below, which further illustrates to 
which degree the single parameters were affected. In cluster I oedema played no role, 
whereas moderate hypoxemia, increased H or neutrophils were present in some groups. 
Cluster II is characterised by physiological dysfunction, with almost no inflammatory aspects. 
In the last two clusters all parameters were increased, whereof albumin leakage was affected 
to a lesser degree than the other injury criteria in cluster III. Notably, all parameters were 
highest in cluster IV. In addition, the four injury criteria were also clustered, showing that 
hypoxemia and H correlated very well with each other and also albumin leakage correlated 
with neutrophils counts. 
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Fig. 3.38: Concluding cluster analysis. All groups from the ventilation study at PEEP = 2 cmH2O, the TNF study 
and both acid studies were analysed. One control group with idealised data was added. Four parameters were 
examined: oxygenation, elastance, albumin leakage and neurophils in the lung. Green coloured fields indicate 
normal values, colourless and pink fields moderate alteration and red fields pathologically changed values. All 
green labelled groups are in cluster I, the red labelled groups lowVTnoRM, lowVTRM60 and SAD belong to cluster 
II and the blue groups MA and MAQ to cluster III. The group SA, labelled in black, stands alone as cluster IV. 
The dendogram reflects how similar groups are to each other. The connecting bars, which carry the colour of the 
corresponding cluster, become shorter with increasing similarity. The parallel plots below illustrate how strong 
each parameter was affected in each cluster. The numbers I-IV denote which cluster is shown in which plot. 
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4 Discussion 
 
The present thesis comprises three approaches that have the potential to cause ALI, namely 
MV, sepsis and acid-instillation, and thereby covers a broad range of pathomechanisms that 
underlie this syndrome. Although the protective aspects of MV as a supportive strategy were 
in the focus in the first study, also injurious settings were examined. The effects of high VT 
ventilation causing over-inflation of the lungs as well as low-volume injury (atelectotrauma) 
were under consideration. The second approach aimed to investigate extra-pulmonary ALI, 
caused by TNF-induced sepsis. Extra-pulmonary ALI differs from intra-pulmonary ALI 
regarding the severity of the disease and also the susceptibility to therapeutic interventions 
[30]. However, this approach did not induce lung injury, so that extra-pulmonary ALI could 
not be further examined. Finally intra-pulmonary lung injury in response to acid-instillation 
was investigated and served as model to examine the effectiveness of steroids in ALI, which 
is still under debate. The employment of different models of ALI takes into account that 
different insults do not necessarily cause the same type or degree of injury. Further, the 
discovery of pathomechanisms that are common in different models of ALI is a prerequisite 
for the development of adequate therapies, considering the widely varied aetiology of this 
disease [47]. 
 
 
4.1 The ventilation model 
The first study focussed on MV under permanent monitoring of lung mechanics and vital 
functions to establish. VILI is the basis for the majority of lung injury models [46]. In addition, 
there is an increasing demand for MV of mice, not only in pulmonary research, but also in 
many other areas such as neurology [150], imaging [151] or cardiovascular research [152]. 
Monitoring of pulmonary and vital parameters is an essential prerequisite for correct 
interpretation of data from such models. Evidence of physiological dysfunction is one of the 
experimental criteria required to prove that ALI has occurred in animal models (Table 1.1). 
To date, most studies on intra-pulmonary ALI omitted the verification of physiological 
dysfunction [47]. Moreover, only a small number of ventilation studies included both, 
monitoring of lung mechanics and physiological key parameters, over several hours 
(Table 1.2).  
 
4.1.1 The importance of recruitment manoeuvres in mechanical ventilation of mice 
The present study indicates that the general notion according to which low VT and sizable 
PEEP levels are preferable is – at least in healthy mice – only true when repetitive RM are 
applied. The effects of repetitive RM are not well established neither in experimental animals 
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nor in men, one reason being that trials that were performed under unequal conditions are 
difficult to compare [143]. To date, application of RM in patients with healthy lungs has been 
explored only sporadically [153], although there is some evidence that RM may support 
protective ventilation by improving oxygenation and lung mechanics, thereby allowing 
reduction of VT [154,155]. Clinically, it has been shown that low VT ventilation improves the 
outcome of patients with injured lungs [39], and also reduces inflammation in those with 
healthy lungs [156]. Taken together, it seems highly important to gain more information on 
the effects of repetitive ‘sigh-like’ RM during low VT ventilation. 
 
The ventilation experiments demonstrated that application of deep inflations of 1 s duration 
and 30 cmH2O peak pressure in five minute intervals was sufficient to keep respiratory 
mechanics stable and thereby lung volume constant in low and high VT ventilation, without 
increasing PEEP over 2 cmH2O (Fig. 3.1). Initially a relatively low PEEP level was selected, 
because the same PEEP was planned to be used in the next studies, in which injurious 
insults were administered, and high PEEP levels are known to be protective (many VILI 
models use no PEEP at all). Since RM can be performed with varying duration, peak 
pressure and end-expiratory pressure [157], a very short type of RM was chosen, which was 
considered to be non-injurious to the lung and not to impair cardiac output. Accordingly, MAP 
and HF were stable, regardless of the ventilation strategy. Although MAP was in a low range 
due to anaesthesia with pentobarbital, so that small changes might have been masked, this 
did not result in reflex tachycardia or impairment of microcirculation, as the pH values 
indicate (Table 3.1). These stable cardiovascular conditions were also guaranteed by several 
supportive measures such as constant fluid support (200 µL/h), regular administration of 
pentobarbital via an intraperitoneal catheter, and an automated system to keep the body 
temperature constant. Further, it can be speculated that the low blood pressure is protective 
in this model, since oedema formation is generally aggravated by high blood pressure. 
 
In order to keep blood gases stable, the low and high VT groups had to be ventilated with 
different respiratory rates and, based on other studies [158], it cannot be completely ruled out 
that this might have affected the outcome of the study. The conditions were chosen to 
provide the same minute volume at both VT. The supplementation of 3% CO2 to the inhaled 
gas mixture in the high VT groups was adequate to prevent hypocapnia, which otherwise 
would have occurred at a respiratory rate of 90 min-1 in the highVTRM5 group. 3% CO2 alone 
did not induce hypercapnia. Thus, a protective effect of hypercapnia during MV, which has 
been described in several studies [159,160], seems unlikely. 
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A pressure of 30 cmH2O for each RM was necessary to maintain lung volume stable. In 
accordance with previous studies [127,129] RM with 25 cmH2O peak pressure were not 
sufficient to avoid a loss of lung volume (data not shown). The double sigmoidal nature of the 
murine pressure volume curve [161] may explain the positive response to RM with 30 cmH2O 
pressure. According to Zosky et al. [161], pressures above 20 cmH2O induce fundamental 
changes in the murine lung, resulting in increased compliance. These changes are proposed 
to be either due to reopening of collapsed alveoli or to a secondary population of alveoli that 
are present but not aerated below a critical transpleural pressure [162]. In the present study, 
measurement of lung input impedance revealed that the alterations in pulmonary resistance 
and compliance in RM60 and noRM mice were predominantly due to changes in the 
periphery of the lung. Although significant differences in Raw between RM5, RM60 and noRM 
mice ventilated at the same VT were observed, this effect was rather small, indicating that 
bronchoconstriction of large airways is of minor importance to explain the present findings. 
The strong increase in G and H in mice ventilated without RM demonstrates a progressive 
loss in lung volume [16]. Increases in G reflect energy dissipation and are associated with an 
increase in tissue resistance and/or regional heterogeneity as result of peripheral airway 
constriction, whereas H reflects energy storage in lung tissues and represents lung stiffness 
[127]. The small decrease in η shows that H increased slightly stronger than G. Usually η 
ranges between 0.1 and 0.2, indicating that elastic and frictional energy is coupled in the 
structures of the lung [25]. The present data underline that impaired lung functions were not 
primarily due to heterogeneity caused by narrowing of small airways [163]. Thus narrowing of 
conductive airways played only a minor role in this model and it can be concluded that the 
loss of lung volume was mainly due to formation of atelectasis. 
 
In fact, lung volume declined only to a certain threshold and a plateau phase was reached in 
all mice ventilated without RM. This supports the hypothesis that depending on the pressure 
applied to the lung some populations of alveoli are open and others closed [161]. The 
minimal lung volumes in the plateau phase differed according to the employed VT, leading to 
the highest G and H values in the lowVTnoRM group. Formation of atelectasis was more 
severe in low VT than in high VT ventilation, as shown elsewhere [128,129], indicating that 
low VT ventilation without RM is injurious. These findings are in line with a previous work 
showing that low VT ventilation augmented lung injury in isolated rat lungs, proposing that the 
degree of lung injury is dependent on the end-expiratory lung volume [164]. Ventilation with 
high VT resulted in a higher C and thereby to some degree protected from the decline in lung 
volume. However, the application of one RM per hour was not sufficient to keep G and H 
entirely stable over six hours, demonstrating that the beneficial effect of recruitment is 
transient and formation of atelectasis is reversible only to a certain point. The present data 
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emphasise the importance of frequent deep inflations in mice in order to maintain lung 
functions in a physiological range. 
 
Further evidence for the formation of atelectasis was given by blood gas analysis, which 
revealed impaired gas exchange in lowVTnoRM and lowVTRM60 mice (Fig. 3.3). The present 
study demonstrates that impairment of gas exchange, to a level that would fulfil the clinical 
definition for ARDS (Table 1.1), can be caused by a ventilation strategy that leads to 
derecruitment of lung volume. On the other hand, the data on lung histopathology, neutrophil 
count and BAL levels of pro-inflammatory cytokines indicate that inflammatory lung injury 
was not severe even in the lowVTnoRM group. Notably, neutrophil counts and 
histopathological alterations (Fig. 3.6, 3.7, 3.8) did not correlate well with gas exchange and 
lung functions, further supporting the conclusion that atelectasis rather than inflammation 
was the major reason for the impaired gas exchange in the groups ventilated without 
sufficient RM. In fact, neutrophil infiltration was highest in the high VT groups, suggesting 
ventilation-induced inflammation (biotrauma) as a mechanism. 
 
Nonetheless, protein leakage, indicating increased microvascular permeability, another 
hallmark of VILI, was highest in those low VT groups that developed atelectasis due to 
lacking adequate RM (noRM, RM60) (Fig. 3.4). Collapse of lung units is accompanied by an 
increase in vascular filtration pressure, leading to oedema formation, when vascular barrier 
functions are impaired [165]. This is in line with the observed alveolar septal thickening. 
Furthermore, microvascular leakage may also interfere with pulmonary surfactant, thus 
contributing to a reduction of compliance [166], which was clearly present in this model. 
Finally, in atelectatic lungs shear forces between closed and open alveoli may develop [37]. 
Taken together it can be concluded that a lack of RM may cause what has been termed 
atelectotrauma. 
 
The present study demonstrates that repetitive RM are not only beneficial for lung functions, 
gas exchange and barrier function, but also reduce the liberation of pro-inflammatory 
cytokines (Fig. 3.5). This is an important finding, because in theory frequent deep inspirations 
might be a trigger for stretch-induced pro-inflammatory mediator release. IL-6 and KC were 
increased in the BAL and blood serum of all ventilated mice and it appears that ventilation 
will always cause mild inflammation in the lungs, both experimentally [132,133,167] and 
clinically [168,169]. The underlying mechanisms may be related to the surgery or 
mechanotransductive processes, i.e. stretch-activation of signalling cascades, or to 
increased vascular shear stress in those groups ventilated with higher positive pressures 
[170]. IL-6 and KC were significantly lower in the BAL fluid of lowVTRM5 mice compared to 
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all other groups, demonstrating that this ventilation strategy was the most protective one. It is 
well established that protective ventilation, minimising overdistension and recruitment / 
derecruitment of the lung, attenuates cytokine liberation in the lung and circulation [171]. 
Interestingly, the blood serum of both VT groups ventilated with RM5 contained significantly 
lower levels of IL-6 and KC than the corresponding groups ventilated with RM60 or noRM. 
This shows that the RM5 procedure was also protective at higher VT. The high levels of IL-6 
and KC in the BAL of highVTRM5 mice indicate that the inflammatory response was initiated 
in the lung. Notably, neither levels of IP-10 nor of TNF - two cytokines that are frequently 
found in severe forms of ALI - were altered significantly in ventilated mice, compared to 
unventilated controls. The relatively high baseline values for TNF in unventilated mice are 
most likely due to the fact that BAL samples had to be diluted in order to gain enough volume 
for the assay. Concentrations were calculated by multiplication with the dilution factor, 
possibly leading to higher concentrations than actually present in the BAL. Nevertheless, all 
groups were analysed at the same time and cytokine levels were in the same range in all 
groups, allowing a comparison. IP-10 is proposed to play a role in development of ARDS and 
is further considered as a useful biomarker for lung disease [172,173]. TNF is considered as 
a mediator of pulmonary inflammation released by injurious ventilation [92,174]. The finding 
that these mediators remained unaltered by ventilation further suggests that lung injury was 
only moderate in the current model. 
 
4.1.2 The role of positive end-expiratory pressure in mechanical ventilation of mice 
This study aimed to define settings for ventilation under stable conditions and therefore a 
second set of experiments was performed with a PEEP of 6 cmH2O, to address the question 
whether a higher PEEP could prevent the severe impairment of lung functions and the 
effects on oxygenation and inflammation, which were observed in the lowVTnoRM and 
lowVTRM60 groups ventilated with a PEEP of 2 cmH2O. Lung mechanics and blood gas 
results revealed that a higher PEEP, even when combined with RM60, was not sufficient to 
prevent formation of atelectasis (Fig. 3.9). C decreased and R, G and H increased strongly 
during the first 180 min of the experiments in the PEEP6_noRM group before parameters 
reached a plateau. A previous study demonstrated that an increase in PEEP from 2 cmH2O 
to 6 cmH2O alone did not prevent an increase in Raw, G and H during 150 min of ventilation, 
but was more effective during pressure controlled RM [127]. The present study shows that a 
combination of higher PEEP and short RM every 60 minutes does not suffice to prevent 
impairment of lung functions and oxygenation and that frequent RM are required, as with a 
PEEP of 2 cmH2O. Of note, the increase in Raw, which was observed in the groups 
lowVTnoRM and lowVTRM60 ventilated with a PEEP = 2 cmH2O, was completely abolished 
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in all groups ventilated with a PEEP = 6 cmH2O, indicating that a higher PEEP helps to 
prevent narrowing of large airways during MV. 
 
It is well known that PEEP plays a critical role in preventing/reducing lung injury [147]. The 
combination of low VT and high PEEP has already proved to be beneficial for the outcome of 
patients with ARDS [175]. Further, an experimental ventilation strategy using low VT, PEEP 
and RM resulted in a better outcome in ARDS patient than a strategy without RM, although 
differences were not significant due to limitations of the trial [176]. Given the significance of 
biotrauma [177,178], it is an important question whether a ventilation strategy that combines 
high PEEP with RM attenuates pulmonary inflammation during low VT. The second part of 
this ventilation study showed that differences in cytokine levels between mice ventilated with 
the same RM strategies were smaller with 6 cmH2O than with 2 cmH2O PEEP. IL-6 serum 
levels were even in a comparable range in all PEEP6 groups (Fig. 3.11). Interestingly, the 
highest IL-6 and KC BAL levels were detected in the PEEP6_noRM group. This correlates 
well with the neutrophil count that was also highest in this group. Thus, the application of RM 
appears to be beneficial with respect to pulmonary inflammation also at a PEEP of 6 cmH2O. 
 
 
4.2 The TNF model 
The pro-inflammatory cytokine TNF is an important mediator in the development of several 
pulmonary diseases, including asthma, COPD and ALI [100]. In experimental studies, the 
effect of TNF on the lung was frequently examined ex vivo in isolated perfused lungs, where 
the systemic circulation and the immune system play no role [90,97,98,179] or in vitro on 
vascular endothelial cells alone [102], where TNF caused a disruption of the microvascular 
barrier. In vivo studies examined either the effect of TNF directly administered to the 
respiratory system, i.t. [180] or intra-nasally [89]. Only in two cases TNF was applied 
systemically, but as continuous infusion [93,94]. All these studies in the past focussed on 
oedema formation and the underlying mechanisms, but measurement of lung functions or 
oxygenation was not performed. The second part of the present thesis, in which the effects of 
high systemic TNF levels on the lung were studied, demonstrates that TNF alone does not 
suffice to induce lung injury in vivo.  
 
4.2.1 The effects of high systemic TNF levels on the lung 
Measurement of the input impedance of the lung revealed that i.v. injection of 50 µg murine 
TNF per mouse, a dosage that can be regarded as lethal, had no relevant influence on the 
tissue properties, indicated by G and H, or on the airways, indicated by Raw (Fig. 3.13). Blood 
gas analysis further supported that TNF did not cause functional impairment of the lung, 
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since gas exchange was in the range of healthy mice in all groups despite of the TNF-
application. This surprising finding led to the question, whether the injected TNF had actually 
arrived in the lung. Due to its physiological function, the blood turnover in the lung is very 
high so that i.v. injected substances reach the lung very quickly. Quantification of TNF via 
ELISA showed that in fact high levels (~1 ng/mL) were detectable in the BAL fluid and even 
103-fold higher concentrations (~1 µg/mL) in the blood plasma (Fig. 3.15). Interestingly, the 
very high plasma levels of TNF were mirrored by high plasma levels of the cytokine IL-6 and 
the neutrophil-attracting chemokine MIP-2. Both mediators were only moderately increased 
in the lung and particularly MIP-2 levels were very low in the BAL fluid. This finding indicates 
that the chemotactic gradient was directed towards the vascular side in TNF-treated mice. 
The observation that neutrophil counts were not increased by TNF, but in a range that can be 
regarded as normal for ventilated mice, as shown in the first study, further supports this 
hypothesis. Furthermore, microvascular permeability, assessed by quantification of BSA-
influx over the alveolar-capillary barrier, was not increased by TNF compared to literature 
values [130]. Unfortunately, the permeability index measured in the TNF study could not be 
directly compared to the index assessed in the previous ventilation study, because a different 
ELISA kit had to be used for BSA quantification. Finally the histopathological scoring 
confirmed that the high concentration of circulating TNF did not generate neutrophilia or any 
other pathological alteration within the given time frame of 6 h. 
 
This is in contrast to the findings observed in models, where TNF was administered directly 
to the lungs and triggered neutrophil recruitment and oedema formation [89,180]. The role of 
TNF in oedema formation is well established [73], posing the question, why the integrity of 
the alveolar-capillary barrier had not been affected in the current investigation. As mentioned 
above, the high amount of circulating TNF seemed to have directed the chemotactic gradient 
towards the vascular side, whereby the neutrophils were possibly held back in the circulation 
instead of sequestering the lung. TNF-induced oedema was shown to be neutrophil-
dependent [90,98,181] and furthermore it was demonstrated that TNF-related oedema 
requires interaction of the integrin complex CD11/CD18, which is located on the neutrophils, 
and the endothelial receptor ICAM-1 [97]. This allows the conclusion that the lack of 
neutrophils in the lungs possibly prevented oedema formation in this study. Although TNF 
sufficed to cause endothelial damage without neutrophils in cell culture experiments 
[182,183], it has to be taken into account that around 40 cell types interact with each other in 
the lung, so that the in vivo situation cannot be compared exactly to in vitro conditions. In 
contrast to the findings in the current investigation, a study in sheep, which were infused with 
0.01 mg/kg human recombinant TNF for 30 min, resulted in a pathophysiology comparable to 
endotoxin-induced lung injury, including hypoxemia and increased pulmonary microvascular 
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permeability [93]. In sheep, leukocyte numbers in the circulation were reduced in response to 
TNF treatment, indicating that TNF enhances neutrophil adherence to the endothelium and 
thereby promotes accumulation of neutrophils in the lung, as it is also the case for endotoxin 
[93]. As there are parallels between TNF- and endotoxin-induced lung injury, probably 
species differences in the mononuclear phagocyte system, which play a role in endotoxin-
induced lung injury, have to be taken into account, when comparing the effects of TNF on the 
lungs of sheep and mice. Interestingly, species that possess pulmonary intravascular 
macrophages (PIM) such as sheep localise endotoxin from the blood to the lung, but species 
without PIM, such as rodents, localise endotoxin to other organs that contain intravascular 
macrophages e.g. liver or spleen [46]. The effect of systemically applied endotoxin is 
therefore only moderate in mice compared to sheep, suggesting that the same may be true 
for TNF. Of note, the i.v. infusion of TNF (0.1 mg/kg/day) in rats over 5 days had an effect on 
the lung, resulting in an increase in lung weight by 38%, although no direct effect on 
membrane permeability was observed [94]. The potency of TNF in this study can probably be 
assigned to the long period of infusion, which discerns this investigation from other 
experimental approaches. The influence of continuously high TNF levels on pulmonary 
inflammation was further demonstrated in mice overexpressing TNF in type II pneumocytes. 
These mice developed pulmonary inflammation and emphysema within a few weeks only 
[184]. The time limitation in the present study might be one reason, why the lung was not 
affected by TNF. It would certainly be interesting to examine whether other organs such as 
the kidney, the liver or the spleen were affected. 
 
There is also evidence that TNF has a less injurious effect on healthy than on pre-damaged 
lungs. In isolated perfused rodent lungs, TNF failed to induce lung injury in un-injured lungs, 
whereas microvascular permeability was aggravated by TNF in ischemic or endotoxin-
challenged lungs [90,179]. Even the i.t. application of 500 ng TNF into healthy rat lungs in 
vivo induced only moderate recruitment of neutrophils and microvascular leakage within 5 h 
[180]. These findings suggest that TNF has a stronger injurious effect when inflammation is 
ongoing and other mediators are also active. In line with this consideration, TNF was shown 
to exacerbate pulmonary inflammation by inhibiting the clearance of apoptotic cells by 
alveolar macrophages [185]. In models of intra-pulmonary lung injury, including endotoxin-
induced lung injury and VILI, blocking of TNF activity by antibodies, repression of TNF 
generation or inhibition of the p55 receptor attenuated lung injury, showing that TNF plays a 
role in the pathophysiology of ALI in injured lungs [57,91,92,181,186]. The critical role for 
TNF in inflammatory respiratory diseases is further shown by the ongoing investigation of 
anti-TNF therapies in clinical trials with asthma and COPD patients (source: NIH 
ClinicalTrials.gov). 
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Finally, the dual role of TNF in pulmonary oedema has to be also taken into account in the 
current study [73]. The protective properties of the lectin-like TNF domain, which promotes 
alveolar fluid clearance, might have been beneficial in the situation given in this model, 
where TNF was increased in the lung, but to a lesser degree than in the vasculature.  
 
4.2.2 The role of acid sphingomyelinase (ASM) in lung injury 
The present study also aimed to elucidate the role of ASM in the lung, by including ASM-/- 
mice. The background for this investigation is the well-known role of ASM in the 
pathophysiology of ALI. Several mechanisms were proposed, by which the promotion of 
pulmonary oedema is linked to ASM activity [99], particularly also when TNF is present 
[109,111]. Further, it is well established, that TNF activates ASM [107,117,187], which was a 
further reason for the examination of ASM-/- mice in this approach. 
 
The present model turned out to be not suitable to further elucidate the role of ASM in ALI, as 
no significant lung injury was induced by the high TNF dosage, as described above in detail 
(chapter 4.2). Interestingly, some parameters indicated that ASM-/- mice were affected 
stronger by TNF-treatment than the wt mice. BAL cytokine levels were higher in the TNF-
treated group ASM-/--zVAD than in the corresponding wt group wt-zVAD (Fig. 3.15). Also 
neutrophil counts were higher in the group ASM-/--zVAD than in the group wt-zVAD, although 
this was not reflected by a significant difference in microvascular permeability (Fig. 3.16). 
This is contrary to previous studies on intra-pulmonary lung injury, in which ASM-deficiency 
or pharmacological inhibition of ASM were protective [118,119,188]. As mentioned above, 
TNF plays a pivotal role in injured lungs. The course of disease in type B NPD patients 
shows that general ASM-deficiency is actually not protective, but causes progressive lung 
injury [124]. Also in the mouse model of NPD, the lungs are a site of the characteristic lipid 
storage phenomenon. Lipid storage is most severe in the monocyte-macrophage system, 
leading to accumulation of mononuclear cells (foamy cells) filled with cytoplasmatic lipid 
inclusions, which are responsible for alveolar congestion [189]. Although only young ASM-/- 
mice under 12 weeks age were included in this study, in order to avoid an influence of lipid 
storage, histopathological examination of the lungs revealed that the accumulation of foamy 
cells had already begun (Fig. 3.17), suggesting that these lungs were slightly more 
susceptible to increased TNF levels than the healthy lungs of wt mice. In this context it has to 
be pointed out that the group ASM-/-sham, which received no pharmacological treatment, 
revealed the most obvious signs of alveolar-capillary barrier disruption, with an extremely 
high number of alveolar neutrophils and a strongly increased albumin leakage. In fact, TNF-
treatment had actually evolved a protective effect in ASM-/- mice, further promoting the 
hypothesis that TNF had directed the chemotactic gradient towards the vascular side. 
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4.2.3 Cardiovascular effects of TNF 
The LD100 of murine TNF ranges between 15-50 µg in mice [78,117,190]. The TNF-induced 
lethality is possibly due to severe cardiovascular depression, as described in detail below. In 
preliminary experiments, the C57BL/6x129/SvEv hybrid mice, which were used in this study, 
were found to be relatively resistant to TNF so that 50 µg per mouse (~ 2 mg/kg) were 
administered here. The present setup proved to be adequate to avoid lethal cardiovascular 
decompensation during the 6 h of ventilation after TNF injection in most mice. 
 
Blood gas analysis elucidated that TNF-treated mice suffered from severe metabolic 
acidosis, a sign of impaired microcirculation, as it occurs in sepsis. As body temperature and 
breathing rate were manipulated in the current setup, parameters which are determined 
clinically as evidence of sepsis, the sepsis marker procalcitonin (PCT) was quantified to 
verify that sepsis was induced by TNF. The pro-hormone PCT correlates with the severity of 
sepsis and is activated in response to infections by the release of cytokines including TNF. 
Therefore PCT has also been termed a hormokine [191]. Although no injurious effect on the 
lung could be assigned to the high TNF levels, the high PCT levels > 2000 ng/L indicated 
that sepsis was induced by TNF within 6 h and that the high systemic TNF dose resulted in a 
pathophysiological reaction similar to that occurring with endotoxin.  
 
The role of TNF in sepsis has been addressed also in clinical trials, where inhibition of TNF 
resulted in reduced mortality [80,83,84]. On the other hand, the clinical use of TNF as a drug 
in cancer-therapy has been considered, but was found to be limited by its toxicity. In clinical 
trials, which examined the systemic application of TNF, hypotension was characterised as 
the dose-limiting factor [192]. In fact, progressive hypotension as well as tachycardia were 
observed also in this study, although only four mice died during the experiment due to the 
supportive strategies, which included fluid support, regulation of body temperature and 
ventilation. The observed cardiovascular decompensation can be regarded as manifestation 
of sepsis [193], allowing the conclusion that TNF actually induced sepsis in this study. 
 
4.2.4 The role of ASM in TNF-induced sepsis 
The present study demonstrated that ASM-/- mice were protected from cardiovascular 
depression and mortality in TNF-induced shock, indicating an important role of ASM in the 
pathogenesis of septic shock. This is in line with the finding that increased ASM levels 
correlated with the development of sepsis in patients, where ASM is regarded as potential 
therapeutic target [114]. Interestingly, ASM-/- mice were shown to be also resistant to 
endotoxin-induced mortality in an earlier approach [117]. Furthermore, the mechanisms of 
TNF- and endotoxin-induced shock were largely identical in that study. A lethal dose of TNF 
 Discussion  
  83  
had the same effects as a lethal dose of endotoxin, causing ceramide generation within 1 h, 
followed by endothelial apoptosis beginning after 6 h and lethality from 10 h onward, 
suggesting that endotoxic shock derives from ceramide-induced widespread microvascular 
endothelial apoptosis, from which ASM-/- mice are protected. However, the cardiovascular 
effects in TNF-induced shock were not addressed in that context [117]. 
 
A potential mechanism by which ASM could be involved in promotion of cardiac 
decompensation in response to TNF is the activation of NO synthases by ceramide, leading 
to NO liberation and vasodilatation, as it was already shown for the neutral sphingomyelinase 
and eNOS [110,111]. The role of NO in the development of hypovolaemic shock is well 
established [194,195]. To address the hypothesis that reduced NO liberation was responsible 
for the protection from mortality in ASM-/- mice in this study total NO was quantified. 
However, the measurement revealed no differences between TNF-treated wt and ASM-/- 
mice, although NO was clearly increased by TNF (Fig. 3.23). From this result, a participation 
of ASM in NO liberation can not be concluded. To validate the loss of ASM enzyme activity in 
the ASM-/- groups, ASM activity was assessed in the urine, whereby it was proved that the 
ASM was defective (Fig. 3.24). It has to be taken into account that NO quantification can be 
affected by haemolysis, as already mentioned in the results. Haemoglobin was shown to 
interfere with NO reduction, leading to reduced NO levels in haemolysed plasma samples 
[149]. Of note, haemolysis was present particularly in plasma samples of wt mice, indicating 
that the suggested NO activating pathway cannot be excluded completely. The role of NO in 
TNF-induced shock has been already examined in previous animal models, where inhibition 
of NO reversed hypotension, but did not protect from TNF-induced organ damage and 
lethality. It has been suggested that NO mediates not only vasodilatation, but also protective 
effects [190,196]. This is further strengthened by a clinical trial on a NO synthase inhibitor in 
septic patients, which had to be stopped, because mortality was significantly increased in the 
treatment group [197], leading to the conclusion that the mechanism by which ASM mediates 
TNF-induced lethality has to be investigated further in the future. 
 
4.2.5 The role of ASM in caspase-independent apoptosis 
Caspase-inhibition was originally considered as a potential therapeutic way of reducing 
apoptosis, which contributes to many diseases [78]. In murine models, treatment with zVAD-
fmk protected from TNF-induced liver injury and apoptosis [198] and also TNF-induced 
enterocyte apoptosis was reduced by caspase-inhibition [199]. In consequence, a further 
study aimed to investigate the mechanisms of systemic toxicity of lethal TNF concentrations 
under caspase-inhibition. Surprisingly, caspase-inhibition by zVAD-fmk enhanced TNF-
induced toxicity by caspase-independent pathways [78]. Also in cell culture experiments, an 
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increased sensitivity to TNF-induced programmed cell death was found in response to zVAD-
fmk [200]. Further, degradation of ceramide and inhibition of ASM resulted in increased cell 
survival after TNF-treatment [125], indicating that ASM played a role in TNF-induced cell 
death. In a study addressing the effects of TNF on the liver in ASM-/-mice, these were shown 
to be protected from hepatocellular cell death [201]. The present study investigated for the 
first time the role of ASM TNF-induced caspase-independent cell death in the lung. 
 
Application of the general caspase-inhibitor zVAD-fmk had no relevant influence on TNF-
treated wt or ASM-/- mice in this study. Interestingly, neither the cardiovascular parameters 
nor mortality were affected by caspase-inhibition, although a strong accelerating effect on 
mortality had been demonstrated in the study by Cauwels et al. [78]. In that study, increased 
TNF-toxicity after caspase-inhibition was shown to originate from an increase in 
phospholipase 2 (PLA2), which is regulated by caspases. The PLA2 causes oxidative stress 
when producing arachidonic acid, the precursor of prostaglandins and leukotrienes. It is very 
likely that not only the generation of ROS, but also the production of pro-inflammatory 
leukotrienes and prostaglandins played a role. The direct inhibition of 5-lipoxygenase, which 
produces leukotrienes, but not the inhibition of cyclooxygenases, which produce 
prostaglandins, improved survival. Nevertheless, the fever inducing prostaglandin PGE2 was 
shown to be induced strongly in response to systemic TNF application in sheep [93] and 
body temperature was not assessed in the study by Cauwels et al.. Therefore in the present 
study, the stabilisation of body temperature may have played a particularly important role, as 
it prevented hypothermia that corresponds with fever in mice and might have prevented a 
more rapid death of zVAD-fmk-treated mice. Furthermore, the high fluid support given by the 
permanent intra-arterial infusion of 200 µL/h 0.9% NaCl plus the i.v. injections of 340 µL 
volume in total may have masked potential effects of zVAD-fmk on the systemic circulation. 
In conclusion, the supportive strategies, which were necessary to investigate the effects of a 
lethal TNF dose in vivo over a time frame of 6 h might have been responsible for the 
inefficacy of caspase-inhibtion. 
 
Unselective caspase inhibition affects not only the induction of cell death but also 
inflammation. The activation of the pro-inflammatory cytokines IL-1β and IL-18 requires 
cleavage by the serine protease caspase-1 [202]. In conclusion, blocking of caspase-1 
should attenuate inflammation, particularly by inhibiting IL-1β, which plays a pivotal role in 
inflammation [203]. In the present study, IL-1β was measured as indirect proof that caspase-
inhibition by zVAD-fmk had functioned. However, this could not be shown, because IL-1β 
was below the detection limit, also in samples from mice that were not treated with the 
caspase inhibitor, indicating that the TNF treatment had not triggered IL-1β release.  
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Only relative cell death in the lung, which was increased per se in ASM-/- mice, possibly due 
to the onset of lipid storage, was slightly reduced by zVAD-fmk, although this effect was not 
significant (Fig. 3.18). Of note, relative cell death was measured by quantifying mono- and 
oligonucleosomes, which does not allow to differentiate between apoptotic and necrotic cell 
death. Although the fact that cell death was higher in ASM-/- mice indicates that the induction 
of necroptosis by TNF via ASM played only a minor role in the lungs. Necroptosis is a 
mechanism by which ASM induces ceramide-dependent cell death in response to TNF. This 
pathway involves activation of the kinase Rip1 by the p55 receptor. Necroptosis is 
distinguished from apoptosis not by the initiating stimuli, which can be the same, but by the 
characteristic morphological changes [204], which could not be analysed in detail here. The 
high level of relative pulmonary cell death in the TNF-treated groups might result from an 
impaired apoptotic cell clearance, which was shown to be caused by TNF in the lung [185]. 
The role of ASM in caspase-independent cell death could not be unravelled in the current 
model, because neither an increase in cell death was induced by zVAD-fmk in wt mice, nor a 
reduction of cell death was observed in ASM-/- mice. This can be assigned to the 
circumstance that TNF had no clear effect in the lung on the one hand as well as to the lipid 
storage disorder on the other hand. Of note, TNF also activates anti-apoptotic pathways via 
the transcriptionfactor NFкB [78]. In this pathway also ASM was shown to be involved [107]. 
Therefore, cell death may not only be enhanced via ceramide generation by ASM, but also 
reduced via NFкB. In conclusion, in ASM-/- mice not only ceramide-dependent cell death may 
be reduced, but also the protection of apoptosis by NFкB activation, whereby caspase-
dependent apoptosis may be enhanced. 
 
 
4.3 The acid model 
A third model was established with the aim to induce lung injury by a direct insult. The 
establishment of a reproducible lung injury model was necessary as basis for the 
investigation of therapeutic strategies. The model of acid-induced lung injury was chosen, 
because it is characterised by important features of ALI including hypoxemia. The present 
model stands out from most previous experimental approaches by including the 
measurement of several clinically relevant physiological parameters, thereby facilitating the 
transfer of data obtained from animal models to ALI in humans. In this study, mice were 
ventilated with a high VT, with the aim to augment the acid-induced lung injury by the 
increased VT. Although ventilation was not supposed to be protective, recurrent RM were 
applied so that the effects of acid-instillation on lung mechanics could be studied without 
being affected by the ventilation strategy. 
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4.3.1 The effects of acid-instillation with pH 1.5 
The first approach to induce lung injury with instillation of 50 µL acid with pH 1.5 was 
successful and resulted in strongly impaired lung functions and critical hypoxemia 
(Fig. 3.25, 3.27). The physiological dysfunction was accompanied by a high lethality after 
about 330 min so that experiments were shortened to 300 min, allowing blood gas analysis 
from living mice at the end of the experiment. The control group was instilled with 50 µL of 
0.9% NaCl to examine the impact of fluid administration to the lung. It could be shown that 
lung mechanics were only affected directly after NaCl instillation and were then stabilised, 
resulting in a relatively normal Horovitz index, which was only about 100 mmHg lower than in 
un-instilled ventilated mice. Further analysis revealed that physiological dysfunction in the 
acid-treated mice was associated with a severe inflammatory response, reflected by high 
levels of IL-6 and KC in the BAL as well as in the plasma. Interestingly, also considerable 
levels of TNF were present in the lungs (Fig. 3.28). This had not been the case in the 
ventilation study, where the absence of TNF in the lung was interpreted as a sign of 
moderate inflammation (chapter 4.1.1). This argument implies that the presence of increased 
TNF levels may be interpreted as an indicator of severe inflammation and is based on the 
idea that severe acute inflammation originates from other pathways than a moderate 
inflammatory response, which can be also beneficial [205]. The inflammatory reaction, which 
was not detectable in the control group, was further characterised by a strongly increased 
microvascular permeability, indicated by albumin leakage, and massive neutrophil 
sequestration, observed by cytospin preparation and histopathological examination. In 
conclusion, this model fulfilled all experimental criteria of ALI listed in Table 1.1.  
 
The pathogenesis of acid-induced lung injury has been described already two decades ago 
[50,63], whereas the mechanisms by which acid activates the immune response are not 
completely understood. It has been suggested that the Toll-like receptor 4, which also 
mediates endotoxin-induced signalling, is necessary for the development of acid-induced 
lung injury [206]. Further, a rapid increase in lysophosphatidylcholine (LPC) in response to 
acid exposure was demonstrated [207]. LPC is produced by hydrolysis of the membrane 
protein phosphatidylcholine by PLA2 and is a precursor of dipalmitoylphosphatidylcholine, the 
surface tension reducing component of surfactant [208]. LPC has an important function as 
mediator of acute and chronic inflammation [209], suggesting a potential role for LPC in 
transforming the chemical insult given by acid into an inflammatory response.  
 
Notably, cardiovascular parameters were not affected by this strong inflammatory response 
or the pulmonary dysfunction (Fig. 3.26). It is very likely that the stable cardiovascular 
condition was the result of the volume substitution. The literature is inconsistent about the 
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effect of acid aspiration on haemodynamics. Whereas acid-instillation caused no 
cardiovascular effects in studies with pigs and rabbits [210], hypotension was observed in 
studies with ventilated rats [211,212]. The measurement of MAP indicated that 
dexamethasone had an influence on MAP, although the increase in the group SAD was not 
significant compared with SA and NaCl5h. The induction of hypertension by glucocorticoids is 
a well-known process, although the mechanisms are only poorly understood. One 
explanation is the potentiation of endogenous vasoconstrictors by glucocorticoid receptors on 
vascular smooth muscle cells. Another recently proposed mechanism implicates a decisive 
role of the glucocorticoid receptors on the vascular endothelium [213]. 
 
4.3.2 The effectiveness of dexamethasone in the severe acid model 
Glucocorticoids are widely used anti-inflammatory drugs that act on the transcriptional and 
non-transcriptional level. Although they are very potent also in respiratory diseases e.g. 
asthma, their usefulness in ALI is still under debate [214]. The application of dexamethasone 
had no beneficial effect on lung mechanics or oxygenation after exposure to acid pH 1.5, 
although the inflammatory response was prevented effectively, illustrated by the strongly 
reduced cytokine levels, low neutrophil numbers and decreased permeability index in the 
group SAD compared to the group SA. Acid-induced lung injury is described as a biphasic 
process, in which a first quick response is due to the chemical properties of the acid, followed 
by a later phase in which the immune response plays a role [63]. The failure of 
dexamethasone to improve lung functions and oxygenation could indicate that the 
physiological dysfunction might have not resulted from inflammation, which developed in 
response to the acid exposure, but was directly caused by the chemical burn due to HCl. 
This view is strengthened by the fact that neutrophil recruitment, which usually precedes 
oedema formation and hypoxemia in the pathogenesis of lung injury [47], was circumvented 
by dexamethasone, whereas oedema formation was not completely abolished. From the 
present data it cannot be concluded, which consequences the chemical burn actually had in 
the lung. No evidence for structural changes was found in the small area examined 
histopathologically. Possibly the burn affected only specific structures, such as the elastic 
fibres, which would explain the increase in elastance after acid exposure and might have 
caused microscopically visible changes after a longer period of time. Autopsy cases of 
patients, who suffered from severe chemical burns and died shortly after, show that the early 
phase of chemically induced lung injury is characterised by profound oedema and also 
haemorrhage, whereas no structural changes are visible microscopically [215,216]. In 
contrast, in a patient, who survived a severe chemical burn, but died of a gun shot 3 months 
later, structural changes had taken place in the lung. These included strictures in the 
bronchioles, emphysema, atelectasis and formation of hyaline membranes with infiltration of 
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fibroblasts or collagenation [216], indicating that a chemical burn results in structural changes 
which might aggravate over time. 
 
The negative outcome in clinical trials on steroids in ALI is believed to derive from too high 
dosages at early stages, which strongly repress the immune response, too short therapy or 
abrupt steroid deprivation [217]. In contrast, prolonged treatment with a moderate dose over 
a period of several weeks is beneficial regarding oxygenation, reduction of pro-inflammatory 
mediators and lethality [218,219]. A moderate dose of 1 mg/kg was also administered in the 
present study, suggesting that the time frame of 5 hours was too short for the development of 
a beneficial effect of the steroid, regarding the severity of the injury.  
 
Further, it has to be mentioned that glucocorticoid resistance is a major problem in critically ill 
patients with sepsis or ARDS: Critical illness related corticoid insufficiency (CIRCI) describes 
a syndrome characterised by insufficient corticoid production as well as unresponsiveness to 
steroid therapy [220]. Several mechanisms were proposed to be responsible for steroid 
unresponsiveness. In chronic inflammatory diseases e.g. asthma, resistance to 
glucocorticoids was related to the high concentrations of cytokines, which were proposed to 
reduce the binding affinity of steroids to the glucocorticoid receptor by activating protein 
kinases (p38, JNK and MAPK) and transcription factors (NFкB and Ap-1) [221-223]. 
Furthermore, high cytokine concentrations were related to a defective nuclear localisation of 
the glucocorticoid receptor [224]. It is thinkable that the high cytokine levels in the present 
acid model also influenced the response to dexamethasone, suggesting that the 
glucocorticoid would be more effective if cytokine levels were lower. In addition, oxidative 
stress is discussed to cause steroid resistance, e.g. in COPD patients, where smoking is a 
source of oxidative stress. The proposed mechanism includes that steroids, which inhibit the 
transcription of pro-inflammatory genes by recruiting histone deacetylases (HDAC), become 
ineffective when oxidative stress impairs the activity of HDACs [225]. This mechanism can 
also be relevant when other sources of oxidative stress are involved. In sepsis or ALI, 
oxidative stress can be caused by support with oxygen (FiO2: 0.5-0.6), which is often 
necessary to ensure sufficient arterial oxygenation. Possibly, oxidative stress is also induced 
by acid-aspiration, even when only a low FiO2 of 0.3 is applied. 
 
In conclusion, steroid treatment cannot be regarded as salutary in this severe model of injury, 
since inhibition of the immune response in the early phase of lung injury is not necessarily 
beneficial and dexamethasone did not restore physiological functionality. The negative side 
effects of repressing the immune response were shown in several clinical trials, in which the 
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prophylactic application of steroids in critically ill patients was associated with a higher risk of 
developing ARDS with lethal outcome [41].  
 
4.3.3 The effects of acid-instillation with pH 1.8  
After acid-instillation with pH 1.5 had resulted in pulmonary inflammation and progressive 
pulmonary dysfunction, which was not susceptible to glucocorticoid therapy, a second 
approach was designed in which the insult was attenuated. For this purpose, the pH of the 
acid was raised to 1.8. The correlation of pulmonary compliance with the oxygenation index 
served to be a suitable indicator to assess the time point at which lung injury was severe 
enough to result in hypoxemia (Fig. 3.31). As a result, experiments with acid pH 1.8 were 
prolonged to 330 min. In fact, physiological dysfunction, including lung mechanics and 
hypoxemia, were less pronounced and also the hallmarks of pulmonary inflammation, i.e. 
cytokine levels, alveolar neutrophils and albumin leakage, were mitigated compared to the 
severe acid model, but the experimental criteria for ALI were still fulfilled. The acid-instilled 
group MA differed significantly from the control group NaCl5.5h in all respects, except from the 
histopathological lung injury score. Of note, in the acid-model only the right upper lobe of the 
lung was subjected to histological examination to save tissue for other analysis. Although it 
can be regarded as advantage to gain as much information from one subject as possible, the 
examination of such a small part of the lung was also critical, because not all regions of the 
lungs were always damaged equally by acid-instillation. This might have been one reason, 
why only a small trend towards an accelerated injury score was observed, when comparing 
the group MA with the group NaCl5.5h. Finally, as expected when considering the 
observations in the severe acid model, cardiovascular parameters were not affected by acid 
pH 1.8, but the hypertensive effect of the steroid was slightly more pronounced (Fig. 3.33). 
 
4.3.4 The effectiveness of dexamethasone in the moderate acid model 
Interestingly, dexamethasone not only diminished the inflammatory response, but also 
effectively restored lung mechanics and oxygenation in the moderate acid model 
(Fig. 3.32, 3.34). These findings indicate that the physiological dysfunction in response to 
acid pH 1.8, which took more time to develop than in the severe model, derived from the 
inflammatory reaction and not primarily from the chemical burn. It is well known that a 
chemical burn occurs within a few seconds and that acid is rapidly neutralised in the lung 
[61]. This was also observed in the course of the current thesis, as it was not possible to 
induce lung injury, when acid was administered as an aerosol into the lung, even at pH 1.5 
(data not shown). The only aspect in which the beneficial influence of dexamethasone could 
not be clearly demonstrated was the lung injury score, but this can certainly be ascribed to 
the fact that the moderate injury hardly increased the score. 
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The lower increase of pro-inflammatory mediators in the lung in response to acid with pH 1.8 
may have contributed to the good response to dexamethasone. As it has already been 
discussed, the high cytokine levels might have interfered with the action of the steroid in the 
severe model. Particularly TNF, which has been proposed here to be an indicator for severe 
injury, was elevated only very moderately and a correlation between high TNF levels and an 
inhibition of the nuclear transport of the glucocorticoid receptor has been pointed out 
previously [224]. In addition, also the potential oxidative stress due to the acid treatment 
could have been reduced at pH 1.8, providing a further explanation for the improved 
response to dexamethasone. 
 
The severity of the disease was also found to correlate with the beneficial effect of steroids in 
sepsis. In a meta-analysis including 21 trials on steroids in sepsis a linear relationship 
between the severity of sepsis and the beneficial effect of steroids on mortality was found. 
Steroids improved survival in critically ill patients, whereas they were harmful in less severely 
ill patients, including that in a certain population of patients, which were moderately ill, no 
effect on mortality was observed at all [214]. Although it appears in the current acid study 
that steroids are more potent in mild than in severe lung injury, the inconclusive outcome of 
trials on steroids in ALI and ARDS might be due to a similar linear relationship between the 
effectiveness of steroids and the severity of lung injury. Therefore, a model in which the 
severity of injury can be varied is of great advantage when examining the effectiveness of 
steroids 
 
Apparently, to date only one animal study with inconclusive results has addressed the 
therapeutic effectiveness of glucocorticoids in acid-induced lung injury [226] and in this case 
dexamethasone was administered i.t.. Other models of lung injury, including VILI or 
endotoxin-instillation, returned controversial results, as some showed protective effects on 
neutrophil sequestration and oedema formation [227,228], while other studies revealed no 
beneficial influence on oedema formation, although neutrophil numbers were reduced 
[227,229]. The present study strongly supports that the differential outcome of steroid 
therapy depends on the grade of lung injury, as it was also shown to be the case in 
endotoxin-induced lung injury [227].  
 
4.3.5 The effectiveness of quinine in acid-induced lung injury 
Quinine was the first effective anti-malaria drug used since the early 17th century [230]. 
Besides of the antimalarial effect, also anti-pyretic, anti-inflammatory, anti-arrhythmic, 
analgesic and muscle relaxant properties have been ascribed to this substance. Chloroquine, 
a derivative of quinine, was shown to be beneficial in moderate and severe asthma 
 Discussion  
  91  
[231,232], revealing anti-inflammatory properties in the lung. Further, quinine was capable of 
preventing oedema formation in the lung, as demonstrated in PAF- and endotoxin-induced 
oedema in mice in vivo and in PAF-induced oedema in the isolated perfused rat lung [233]. 
Thus, quinolines exert salutary features, which could also improve the outcome of ALI. 
Therefore, the effects of quinine were examined in the moderate acid model. However, 
despite of the very high dose (20 mg/kg) no beneficial outcome could be found in any aspect 
of injury in the current model. The current data do not indicate why quinine failed to protect 
from inflammation and oedema formation and the mechanisms by which quinine exerts its 
beneficial functions are largely unknown.  
 
 
4.4 Common patterns in the examined injury models 
Each study in the current thesis addressed a different aspect of ALI. Finally the question 
aroused, whether common mechanisms or injury patterns that lead to ALI can be found. 
Therefore the experimental groups from this thesis were compared by cluster analysis under 
consideration of four main aspects of ALI: hypoxemia, elastance, albumin leakage and 
neutrophil infiltration. The cluster analysis revealed that the groups could be assigned to four 
clusters (Fig. 3.38). Cluster I comprised all groups, which did not fulfil the experimental 
criteria of ALI. This cluster included all groups from the TNF study, the control groups from 
the acid models and the high VT groups from the ventilation study, although they had shown 
moderate signs of VILI. Of note, the group lowVTRM5 was very similar to the idealised 
control group, which further indicates that the ventilation strategy with low VT and recurrent 
RM was very protective.  
 
Interestingly, those 6 groups that fulfilled the experimental criteria of ALI were sorted into 
three distinct clusters (II-IV), revealing that they had different injury patterns. Among these, 
the group SA was separated from the other groups, as it showed by far the most severe 
injury. The classification of the steroid-treated group SAD into one cluster with the groups 
lowVTnoRM and lowVTRM60, illustrates that acid pH 1.5 induced not only inflammatory 
processes. After elimination of inflammation by dexamethasone, the remaining injury pattern 
was comparable to the mechanical injury in atelectatic lungs. This was unlike the situation in 
the moderate acid model (cluster III), where lung injury was prevented almost completely by 
dexamethasone, so that the group MAD was sorted to the ‘healthy’ groups in cluster I. This 
indicates that in the moderate acid model only inflammatory, but no mechanical injury, led to 
physiological dysfunction. An interesting future approach would be to examine the 
effectiveness of steroids in atelectatic lungs, to verify that physiological dysfunction did not 
Discussion 
92 
result from inflammation in this case. Nevertheless, it can be concluded that the injury pattern 
determined, whether the glucocorticoid therapy was beneficial in the current acid models.  
 
Transferring this rationale to patients with ALI may provide an explanation why some patients 
benefit from steroid therapy, while others do not. As already pointed out, ALI derives from a 
broad range of aetiologies and, besides of the four defined clinical criteria, the manifestation 
of this syndrome can vary from patient to patient. Thus, the systematic analysis of common 
injury patterns, which allow to predict the susceptibility to steroids, could provide a valuable 
tool to improve the poor outcome of patients with ALI. 
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4.5 Conclusion 
The current thesis analysed the impact of three different injurious stimuli on the lung in a 
setup that facilitated the monitoring of clinically relevant physiological parameters and can 
therefore be regarded as mouse intensive care unit. In the ventilation study, the healthy 
mouse lung was found to be relatively resistant to MV, even when ventilation strategies were 
applied that are regarded as not protective. Application of high VT did not cause relevant lung 
injury, although comparable settings were used in other studies that investigated VILI. 
Nonetheless, ventilation without RM at low VT promoted formation of atelectasis and caused 
physiological dysfunction. This study demonstrates that protective non-injurious ventilation 
requires the application of frequent short RM, low VT and sizeable PEEP to ensure stable 
lung mechanics. 
 
This thesis further indicates that the healthy lung is not very susceptible to inflammatory 
stimuli, when the alveolar-capillary barrier is intact. This was illustrated by the fact that the 
approach to induce extra-pulmonary lung injury by TNF-induced sepsis failed. In general, 
models that aim to induce lung injury by indirect insults result in a weaker lung injury, but 
often have stronger systemic effects than models of intra-pulmonary injury. However, the 
TNF study proved that the mouse intensive care unit established in the course of this thesis 
is useful to study the effects of sepsis on the lung and the cardiovascular system. 
Furthermore, a crucial role for ASM in TNF-induced septic shock was revealed. 
 
In addition, it was shown that acid-instillation allows to induce experimental lung injury with 
variable severity, depending on the pH of the instilled acid. This model was therefore used to 
examine the therapeutic usefulness of dexamethasone. Instillation of acid with a pH 1.5 
produced gross lung injury, characterised by inflammation and profound structural changes 
in the lung, which could not be prevented by the anti-inflammatory treatment. In contrast, 
acid with a pH 1.8 caused predominantly inflammatory processes that were susceptible to 
dexamethasone. A final cluster analysis revealed three injury patterns of ALI, namely 
inflammation, low-volume injury and chemical damage, and validated that the susceptibility to 
steroids depended on the severity and type of lung injury. This analysis indicates that a 
systematic analysis of injury patterns in ALI patients might be a new approach to predict the 
benefit of steroid treatment.
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6 Supplements 
 
6.1 Statistical group comparisons 
The tables below show exemplary, which groups were compared for calculation of the p-
values in the single models. The same groups were also compared in all other analyses 
within those models. 
 
6.1.1 Lung mechanics with PEEP = 2 cmH2O 
Table 6.1: P-values ranges for lung mechanics with PEEP = 2 cmH2O 
 C R G H Raw 
LowVTRM5 – LowVTnoRM 0.001 0.001 0.05 0.001 0.001 
LowVTRM5 – HighVTRM5 n.s. 0.05 n.s. n.s. 0.05 
LowVTRM5 – LowVTRM60a 0.001 0.001 0.01 0.001 0.001 
LowVTRM5 – LowVTRM60b 0.01 0.01 0.05 0.01 0.001 
HighVTRM5 – HighVTnoRM 0.001 0.001 0.05 0.001 0.001 
LowVTnoRM – LowVTRM60b 0.01 0.01 0.05 0.001 0.001 
LowVTnoRM – HighVTnoRM 0.01 0.001 n.s. 0.01 0.001 
LowVTRM60a – LowVTRM60b 0.01 0.05 0.05 0.05 0.01 
 
C: compliance, R: resistance, G: tissue damping, H: tissue elastance, Raw: airway resistance. p ≤ 0.05 was 
considered as statistically significant, n.s. not significant.  
 
 
6.1.2 Lung mechanics with PEEP = 6 cmH2O 
Table 6.2: P-value ranges for lung mechanics with PEEP = 6 cmH2O 
 C R G H 
PEEP6_RM5 – PEEP6_RM60a 0.001 0.01 0.001 0.001 
PEEP6_RM5 – PEEP6_RM60b 0.001 0.05 0.001 0.001 
PEEP6_RM5 – PEEP6_noRM 0.001 0.001 0.001 0.001 
PEEP6_noRM – PEEP6_RM60a n.s. n.s. n.s. 0.05 
PEEP6_noRM – PEEP6_RM60b 0.01 0.001 0.001 0.001 
PEEP6_RM60a – PEEP6_RM60b 0.05 0.05 0.05 0.01 
 
C: compliance, R: resistance, G: tissue damping, H: tissue elastance. p ≤ 0.05 was considered as statistically 
significant, n.s. not significant. 
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6.1.3 Group comparisons for one-way ANOVA analyses in the TNF model 
wt-zVAD – wt+zVAD 
ASM-/--zVAD – ASM-/-+zVAD 
wt-zVAD – ASM-/--zVAD 
wt+zVAD – ASM-/-+zVAD 
ASM-/-sham – ASM-/--zVAD 
ASM-/-sham – ASM-/-+zVAD 
ASM-/-sham – wt-zVAD 
ASM-/-sham – wt+zVAD 
 
 
6.1.4 Lung mechanics in the severe acid model 
Table 6.3: P-value ranges for lung mechanics in the severe acid model 
 C R G H Raw 
NaCl5h – SA 0.001 0,05 0.001 0.001 n.s. 
NaCl5h – SAD 0.001 0.001 0.001 0.001 n.s. 
SA – SAD n.s. n.s. n.s. n.s. n.s. 
 
NACl: control with NaCl it, SA: severe acid (pH 1.5) it, SAD: severe acid it + dexamethasone iv; C: compliance, 
R: resistance, G: tissue damping, H: tissue elastance, Raw: airway resistance. p ≤ 0.05 was considered as 
statistically significant, n.s. not significant.  
 
 
6.1.5 Lung mechanics in the moderate acid model 
Table 6.4: P-value ranges for lung mechanics in the moderate acid model 
 C R G H Raw 
NaCl – MA 0.01 0.01 0.01 0.01 n.s. 
NaCl – MAD n.s. n.s. n.s. n.s. n.s. 
NaCl – MAQ 0.01 0.01 0.01 0.001 n.s. 
MA – MAD 0.01 0.01 0.01 0.001 n.s. 
MA – MAQ n.s. n.s. n.s. n.s. n.s. 
MAD – MAQ 0.01 0.01 0.05 0.001 n.s. 
 
C: compliance, R: resistance, G: tissue damping, H: tissue elastance, Raw: airway resistance. p ≤ 0.05 was 
considered as statistically significant, n.s. not significant.  
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